UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
/X/ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the Fiscal Year Ended December 31, 2002
/ / Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition Period from ________to________
Commission File Number 0-10379
INTERFERON SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware 22-2313648
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
783 Jersey Avenue, New Brunswick, New Jersey 08901
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (732) 249-3250
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, Par Value $0.01 Per Share
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter Period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No --
---- ----
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. / /
As of May 8, 2003, the aggregate market value of the outstanding shares of
the registrant's Common Stock, par value $.01 per share, held by non-affiliates
(assuming for this calculation only that all officers and directors are
affiliates) was approximately $2,902,626 based on the last reported sale price
of such stock on the OTC Bulletin Board on May 8, 2003.
Indicate the number of shares outstanding of each of the registrant's
classes of common stock, as of the latest practicable date.
Class Outstanding at May 8, 2003
--------------------------------------
Common Stock, par value $.01 per share 36,282,823 shares
DOCUMENTS INCORPORATED BY REFERENCE
None.
TABLE OF CONTENTS
Page
Item 1. Business 1
Item 2. Properties 11
Item 3. Legal Proceedings 11
Item 4. Submission of Matters to a Vote of Security Holders 11
Item 5. Market for the Registrant's Common Stock and Related
Stockholder Matters 12
Item 6. Selected Financial Data 12
Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations 13
Item 7A. Quantitative and Qualitative Disclosure About
Market Risk 20
Item 8. Financial Statements and Supplementary Data 20
Item 9. Changes In and Disagreements with Accountants on
Accounting and Financial Disclosure 40
Item 10. Directors and Executive Officers of the Registrant 41
Item 11. Executive Compensation 42
Item 12. Security Ownership of Certain Beneficial Owners
and Management 43
Item 13. Certain Relationships and Related Transactions 45
Item 14. Exhibits, Financial Statement Schedules,
and Reports on Form 8-K 47
PART I
Item 1. Business
(a) General Development of Business
Agreement with Hemispherx Biopharma, Inc. ("HEB")
On March 11, 2003, Interferon Sciences, Inc. ("ISI" or the "Company")
executed two agreements with HEB to sell certain assets of ISI (the two asset
sale transactions are hereinafter jointly referred to as the "Asset Sale
Transactions" and individually referred to as the "First Asset Sale" and the
"Second Asset Sale") and consummated the First Asset Sale.
In the first agreement with HEB (the "First Asset Sale Agreement"), ISI
sold all of its inventory related to ALFERON N Injection(R), ISI's natural alpha
interferon product approved for the treatment of certain types of genital warts
(the "Product"), and granted a limited license for the production, manufacture,
use, marketing and sale of the Product in the United States.
For these assets, ISI:
(i) received 424,528 shares of HEB common stock (the "Common Stock")
(these shares, along with other shares described below as having
a guaranteed value, are sometimes referred to as the "Guaranteed
Shares") which had a Market Value (as defined in the First Asset
Sale Agreement) of $675,000 and a guaranteed value of $675,000;
(ii) received an additional 62,500 shares of Common Stock without a
guaranteed value; and
(iii)will receive a royalty equal to 6% of the net sales of the
Product.
ISI will receive a service fee for providing certain transitional
services. In addition, HEB will assume ISI payables and certain other
obligations related to the Product. This Agreement obligates HEB to register the
Common Stock issued to ISI, sets periodic limits on the number of shares ISI may
sell and requires HEB to pay ISI an amount equal to the product received by
multiplying (i) the number of Guaranteed Shares remaining unsold on March 11,
2005 and (ii) $1.59. The remaining Guaranteed Shares will then be returned to
HEB.
In the second agreement with ISI (the "Second Asset Sale Agreement"),
ISI has agreed to sell, subject to certain approvals, to HEB all of its rights
to the Product and other assets related to the Product including, but not
limited to, real estate and machinery. For these assets, ISI will:
(i) receive 424,528 shares of HEB Common Stock which has a Market
Value (as defined in the Second Asset Sale Agreement) of $675,000
and a guaranteed value of $675,000;
(ii) receive an additional 62,500 shares of HEB Common Stock without a
guaranteed value; and
(iii)receive a royalty equal to 6% of the net sales of any products
containing natural alpha interferon sold by HEB (or a Marketing
Partner, as defined in the Second Asset Sale Agreement)
In addition, HEB will be required to satisfy three obligations of ISI
which aggregate approximately $1,500,000. HEB will be obligated to pay certain
ongoing expenses related to ISI's operations prior to the closing of the Second
Asset Sale Agreement.
The Second Asset Sale Agreement obligates HEB to register the Common
Stock to be issued, sets periodic limits on the number of these shares that may
be sold and requires HEB to pay ISI an amount equal to the product received by
multiplying (i) the number of Guaranteed Shares remaining unsold on the date
which is two years after the closing date of the Second Asset Sale Agreement and
(ii) $ 1.59. The remaining Guaranteed Shares will then be returned to HEB.
The purchase price for the assets was determined by negotiation between
HEB and ISI.
The foregoing descriptions of the Asset Sale Transactions, the First
Asset Sale Agreement and the Second Asset Sale Agreement are qualified in their
entirety by reference to the full text of the First Asset Sale Agreement, the
Second Asset Sale Agreement, which are filed as Exhibits 2.1 and 2.2 to the
Current Report on Form 8-K, dated March 18, 2003, and incorporated herein by
reference.
Set forth below is a description of the business related to ALFERON N
Injection which was sold to HEB.
Interferon Sciences, Inc. (the "Company") is a biopharmaceutical
company which studies, manufactures, and sells ALFERON N Injection(R), a
pharmaceutical product based on its highly purified, multi-species,
natural-source alpha interferon ("Natural Alpha Interferon"). ALFERON N
Injection (Interferon Alfa-n3) is approved by the United States Food and Drug
Administration ("FDA") for the treatment of certain types of genital warts and
we have studied its potential use in the treatment of human immunodeficiency
virus ("HIV"), hepatitis C virus ("HCV"), and other indications. ALFERON N
Injection is currently being studied in cancer and we are also evaluating its
use in the treatment of multiple sclerosis and certain other viral diseases.
(b) Financial Information about Business Segments
The Company operates as a single line of business. For the years ended
December 31, 2002, 2001 and 2000, domestic sales totaled $1,926,466, $1,488,897
and $1,046,470, respectively and foreign sales totaled $-0-, $9,706 and $21,001,
respectively. All identifiable assets are located in the United States.
(c) Narrative Description of Business
Scientific Background
Interferons are a group of proteins produced and secreted by cells to
combat diseases. Researchers have identified four major classes of human
interferon: alpha, beta, gamma and omega. The Company's ALFERON N Injection
product contains a multi-species form of alpha interferon. The worldwide market
for injectable alpha interferon-based products has experienced rapid growth and
various alpha interferon injectable products are approved for many major medical
uses worldwide.
Alpha interferons are manufactured commercially in three ways: by
genetic engineering, by cell culture, and from human white blood cells. In the
United States, all three of these types of alpha interferon are approved for
commercial sale. The Company's Natural Alpha Interferon is produced from human
white blood cells.
The Company believes that the potential advantages of Natural Alpha
Interferon over recombinant interferons may be based upon their respective
molecular compositions. Natural Alpha Interferon is composed of a family of
proteins containing many different molecular species of interferon. In contrast,
recombinant alpha interferons each contain only a single species. Researchers
have reported that the various species of interferon may have differing
antiviral activity depending upon the type of virus. Natural Alpha Interferon
presents a broad complement of species which the Company believes may account
for its higher efficacy in laboratory studies with the HIV virus compared with
that of recombinant alpha interferon 2a and 2b (ROFERON(R) A and INTRON(R) A,
respectively). Natural Alpha Interferon is also glycosylated (partially covered
with sugar molecules). Such glycosylation is not present on the currently
marketed recombinant alpha interferons. The Company believes that the absence of
glycosylation may be, in part, responsible for the production of
interferon-neutralizing antibodies seen in patients treated with recombinant
alpha interferon. Although cell culture-derived interferon is also composed of
multiple glycosylated alpha interferon species, the types and relative quantity
of these species are different from the Company's Natural Alpha Interferon.
The production of Natural Alpha Interferon is dependent upon a supply
of human white blood cells and other essential materials. The Company obtains
white blood cells from FDA- licensed blood donor centers.
ALFERON N Injection
Approved Indication. On October 10, 1989, the FDA approved ALFERON N
Injection for the intralesional treatment of refractory (resistant to other
treatment) or recurring external genital warts in patients 18 years of age or
older. Substantially all of the Company's revenues, to date, have been generated
from the sale of ALFERON N Injection for such treatment. Certain types of human
papillomaviruses ("HPV") cause genital warts, a sexually transmitted disease. A
published report estimates that approximately eight million new and recurrent
cases of genital warts occur annually in the United States alone.
Genital warts are usually treated using caustic chemicals or through
physical removal methods. These procedures can be quite painful and effective
treatment outcomes are often difficult to achieve. The FDA approved a topical
formulation of an interferon-inducer in 1997 for the treatment of genital warts.
To date, the Company does not believe that such approval has had a material
adverse effect on the sales of ALFERON N Injection.
Clinical Trials for New Indications. In an effort to obtain approval to
market ALFERON N Injection for additional indications, the Company has conducted
various clinical trials for new indications.
HIV-infected Patients. The Human Immunodeficiency Virus ("HIV")
infection is at epidemic levels in the world. It currently affects approximately
40 million people. HIV infection usually signals the start of a progressive
disease that compromises the immune system, ultimately resulting in Acquired
Immune Deficiency Syndrome ("AIDS").
An article published in AIDS Research and Human Retroviruses in 1993 by
investigators at Walter Reed Army Institute of Research ("Walter Reed") in
collaboration with the Company's scientists indicated that the various
interferon species display vast differences in their ability to affect virus
replication. Walter Reed researchers found that the Company's Natural Alpha
Interferon was approximately 10 to 100 times more effective than equal
concentrations of recombinant alpha interferon 2a or 2b, in blocking the
replication of HIV-1, the AIDS virus, in infected human cells (monocytes) in
vitro.
Moreover, the Company's scientists were able to separate members of the
interferon family in single protein fractions or clusters of proteins using
advanced fractionation techniques. The individual fractions were tested for
their ability to block HIV replication in the laboratory by researchers at
Walter Reed. They found that the unusual anti-HIV activity was attributable to
very specific fractions in the Company's product. The most active fractions are
not present in marketed recombinant interferon products.
This information provided additional support for a long-held belief of
the Company that its Natural Alpha Interferon has unique anti-viral properties
distinguishing it from recombinant interferon products. In addition, published
reports of trials using recombinant alpha interferon in asymptomatic
HIV-infected patients indicated that while high doses blocked virus production
in many cases, such doses resulted in high levels of adverse reactions, thereby
limiting the usefulness of the recombinant product. These facts led the Walter
Reed researchers to conduct a Phase 1 clinical trial with the Company's product
in asymptomatic HIV-infected patients.
In March 1992, Walter Reed launched a Phase 1 clinical trial in
asymptomatic HIV-infected patients with CD4 white blood cell counts of at least
400 cells per cubic millimeter, to investigate the safety and tolerance, at
several dose regimens, of ALFERON N Injection, self-injected subcutaneously for
periods of up to 24 weeks. The investigators concluded that the treatment was
"surprisingly" well tolerated by patients, at all dose regimens. Preliminary
findings were reported by Walter Reed at the IXth International Conference on
AIDS in Berlin in 1993. The investigators also reported that the expected
interferon side effects, such as flu-like symptoms, were rare or absent in the
majority of patients treated with the Company's product.
Although this Phase 1 clinical trial was designed primarily to provide
safety information on various doses of ALFERON N Injection used for extended
periods of time, there were encouraging indications that certain disease
parameters had stabilized or even improved in certain patients by the end of the
experimental treatment.
In a follow-up analysis of patients' blood testing data, it was found
that while on treatment, the amount of HIV detectable in the patients' blood, as
measured by polymerase chain reaction ("PCR") testing, declined in a dose
dependent manner (the greatest declines were observed in the highest dose
group). Also, none of the patients were found to have developed neutralizing
antibodies to Natural Alpha Interferon, even after being treated three times
weekly for many months. These results were reported at the Third International
Congress on Biological Response Modifiers held in Cancun, Mexico in January 1995
and were selected for a poster presentation at the 35th Interscience Conference
on Antimicrobial Agents and Chemotherapy held in San Francisco in September
1995. An extensive report was published in the May 1996 issue of the Journal of
Infectious Diseases.
It is important to note that, because of the small number of study
participants and the absence of a control group, no firm conclusions can be
drawn from these observations. However, based on the safety and preliminary
efficacy data obtained from this trial and after meeting with the FDA, the
Company conducted a multi-center Phase 3 clinical trial of ALFERON N Injection
in HIV-infected patients, which was completed in December 1997. This randomized,
double-blind, placebo-controlled trial was designed to evaluate the safety and
efficacy of ALFERON N Injection in the treatment of HIV-positive patients, some
of whom may have been taking other FDA-approved antiviral agents. Enrolled
patients were required to have CD4 white blood cell counts of at least 250 cells
per cubic millimeter and a viral burden (as determined by PCR testing) of at
least 2,000 RNA copies per milliliter. The Company completed the analysis of the
data collected from the 16 investigator sites and attended a pre-filing meeting
with the FDA in mid-March 1998. Shortly after that meeting, the FDA advised the
Company that, although ALFERON N Injection demonstrated biological activity in
this Phase 3 clinical trial, the results were insufficient for filing for
approval for this additional indication for ALFERON N Injection. While the
results over the course of treatment demonstrated benefits that were
statistically significant for the group of patients receiving ALFERON N
Injection and highly statistically significant for the subgroup of patients with
high CD4 white blood cell counts (CD4 counts of at least 400 cells per cubic
millimeter, as was studied in the Phase 1 study above), the study's primary
efficacy variable (reduction in viral load) was not met at the time point
specified in the protocol (end of treatment). Because the agreed upon primary
endpoint was not met and in light of the changes in HIV treatment regimen to
simultaneous multiple drug therapy since this trial was designed, the FDA
indicated that an additional trial, in which ALFERON N Injection was studied in
conjunction with multiple drug therapy would be necessary to evaluate further
the efficacy of ALFERON N Injection for this indication.
Hepatitis C. Chronic viral hepatitis is a liver infection caused by
various hepatitis viruses. The United States Centers for Disease Control and
Prevention estimates that nearly four million people in the United States are
presently infected with the hepatitis C virus ("HCV"), a majority of who become
chronic carriers and will suffer gradual deterioration of their liver and
possibly cancer of the liver. Several brands of recombinant interferon and a
cell-cultured interferon have been approved for the treatment of hepatitis C
infection in the United States and by various regulatory agencies worldwide. See
"Business - ALFERON N Injection - Competition." However, reports have indicated
that many patients either do not respond to treatment with the recombinant
products or relapse after treatment. The Company has conducted three
multi-center, randomized, open-label, dose ranging Phase 2 clinical trials
utilizing ALFERON N Injection with patients chronically infected with HCV. The
objective of the Company's HCV clinical studies was to compare the safety and
efficacy of different doses of Natural Alpha Interferon injected subcutaneously
in naive (previously untreated), refractory (unsuccessfully treated with
recombinant interferon), and relapsing (initially responded to recombinant
interferon but later relapsed) patients.
The results in naive patients indicated a significant dose-dependent
response at the end of treatment favoring the highest dose group. In addition,
treatment of naive patients with ALFERON N Injection did not produce any
interferon-neutralizing antibodies. An oral presentation of the results in naive
patients was given at the American Association for the Study of Liver Diseases
("AASLD") meeting that took place in November 1995. The results of this study
were published in the February 1997 issue of Hepatology.
The results in refractory patients indicated a significant
dose-dependent response at the end of treatment favoring the highest dose group.
A poster presentation of the results in refractory patients was given at the
AASLD meeting that took place in November 1995.
Based on the promising results obtained in the study on naive patients,
the study on relapsing patients, which was accruing patients slowly, was
terminated early so that the Company could concentrate its limited resources on
pursuing the Phase 3 trials in naive patients, discussed below.
After meeting with the FDA, the Company commenced in 1996 a Phase 3
multi-center, open label, randomized, controlled clinical trial designed to
evaluate the safety and efficacy of ALFERON N Injection compared to INTRON A in
naive chronic hepatitis C patients. The trial was conducted at 26 sites located
in the United States and Canada and a total of 321 people were treated. The
trial consisted of a 24-week treatment phase and 24-week follow-up and also
included an interim analysis after approximately one-half of the enrolled
patients completed the treatment and follow-up phases.
On April 2, 1998, the Company announced it had completed the interim
analysis of the results for approximately half of the enrolled patients. If the
results of the interim analysis had demonstrated at a very high level of
statistical significance that ALFERON N Injection is effective, the Company
intended to seek FDA approval while continuing to follow the other enrolled
patients. However, while the efficacy analysis indicated that ALFERON N
Injection and the control treatment (an approved therapy) appeared to yield
similar results, the study protocol required a showing of superiority in order
to meet the criteria for statistical significance in the interim analysis.
Therefore, the Company did not seek FDA approval based on the interim analysis.
The Phase 3 study was completed in 1998. The Company completed the final
analysis of the data in March 1999, and met with the FDA to determine the
acceptability of the results for filing purposes. At that meeting, the FDA
advised the Company that the results of the trial were insufficient to file for
approval because the designed endpoint of the trial (which required a showing of
superiority in sustained normalization of liver enzymes at the end of treatment
and after six months of follow up) was not met. Therefore, the FDA informed the
Company that an additional trial would be required to further evaluate the
efficacy of ALFERON N Injection for this indication.
HIV and Hepatitis C Co-Infected Patients. In December 1997, patient
enrollment commenced in a Phase 2 multi-center, open label clinical trial
designed to evaluate the safety and efficacy of ALFERON N Injection in patients
co-infected with HIV and HCV. In May 2000, an abstract entitled "Treatment of
HCV/HIV Coinfection with Leukocyte Derived Interferon Alfa-n3", was published in
Gastroenterology.
Multiple Sclerosis. Multiple sclerosis ("MS") is a chronic, sometimes
progressive, immune-mediated disease of the central nervous system that is
believed to occur in genetically predisposed individuals following exposure to
an environmental factor, such as virus infection. The disease affects an
estimated 250,000 to 350,000 people in the United States, primarily young
adults. Symptoms of MS, including vision problems, muscle weakness, slurred
speech, and poor coordination, are believed to occur when the patient's own
cells attack and ultimately destroy the insulating myelin sheath surrounding the
brain and spinal cord nerve fibers, resulting in improper transmission of
signals throughout the nervous system.
In the United States, two recombinant forms of beta interferon have
been approved for the treatment of relapsing-remitting MS. However, reports in
the scientific literature and elsewhere have indicated that the significant
adverse reactions associated with the treatments may limit their usefulness for
a subset of patients. In addition, Teva Neuroscience, Inc.'s product,
Copaxone(R), a non-interferon product, was approved by the FDA to treat
relapsing-remitting MS.
The Company has received anecdotal reports on the use of ALFERON N
Injection in MS patients. In addition, encouraging reports were presented at a
number of scientific conferences, namely:
"Management of Interferon-(beta)1b (Betaseron) Failures in MS with
Interferon-(alpha)n3 (Alferon N)", Charcot Foundation Meeting, Switzerland,
March 2000,
"Interferon-alfa-n3 (Alferon N) Reduces Gadolinium Enhancing Brain Lesions
in Multiple Sclerosis", XVII World Congress of Neurology, London, UK, June
2001,
"Alferon N (IFN-alfa-n3) and Betaseron (IFN-beta-1b) reduce T2 lesion load
in multiple sclerosis (MS)", 17th Congress of the European Committee for
Treatment & Research in Multiple Sclerosis (ECTRIMS), Dublin, Ireland,
September 2001, and
"Response of MR T2 Lesion Load in Patients with Multiple Sclerosis: A
Retrospective Blinded Study of Treatment with Interferon (beta)1b
(Betaseron) versus Interferon (alpha)-n3 (Alferon N) versus Untreated",
126th Annual Meeting of The American Neurological Association, in Chicago,
October 2001.
This last study was based on the retrospective review of multiple brain
magnetic resonance imaging (MRI) scans to assess MS brain lesion burden. The
study compared the scans of 40 MS patients treated with interferon alfa-n3
(ALFERON N Injection) as well as 40 MS patients treated with interferon beta-1b
(Betaseron(R)), both before therapy and at least six months after initiation of
therapy. A control group of 39 untreated MS patient scans were also evaluated
with an initial MRI scan at baseline and a second MRI obtained at least six
months after the baseline examination. On the 238 scans evaluated (119 patients)
only lesions of larger than 5 mm3 were measured to avoid inclusion of potential
non-MS lesions and assure accuracy of measurement. All scans were reviewed by
consensus of two experienced neuroradiologists who were blinded to all
identifiers, including name, date, order of scans, and clinical status of the
patient.
The study data showed a reduction in the volume of T2-weighted MS brain
lesions in both the interferon alfa-n3 treated group (-10%) and the interferon
beta-1b treated group (-7%), as compared to increased lesion volume in the
untreated control group (+12%).
Changes in disability scores amongst the groups were also
retrospectively reviewed, based on the extended disability status scale (EDSS).
Only patients with EDSS scores recorded both at baseline and after at least 12
months were evaluated, which included 38 interferon alfa-n3 treated patients, 31
interferon beta-1b treated patients, and 33 untreated patients. The results
showed the mean absolute change in EDSS scores from baseline to be -1.07 for
interferon alfa-n3 treated patients and -0.16 for interferon beta-1b treated
patients after 12 months, as compared to +0.80 for untreated patients (negative
changes reflect decreased disability scores, positive change reflects increased
disability scores). The scale of EDSS scores ranges from 0 for a normal
neurological examination to a score of 10 for death due to MS.
This retrospective evaluation does not constitute a prospective
clinical study of the type needed to obtain regulatory approval, and does not
indicate that interferon alfa-n3 will be shown to be effective if such clinical
studies are performed.
Cancer. On April 30, 2001, the Company signed an exclusive technology
license agreement with Mayo Foundation for Medical Education and Research, of
Rochester, MN, for the rights to technology under investigation for preventing
the recurrence of cancer after surgical removal of tumors. As part of the
collaboration with Mayo, Interferon Sciences is funding a clinical trial
entitled "Identification of an Immunostimulatory Dose of Natural Interferon
(Phase A) and Its Impact on Clinical Outcome (Phase B) in Patients with
Melanoma", which commenced in December 2001.
The Company has committed to fund approximately $400,000 of costs
related to this clinical trial. The Company paid Mayo $100,000 related to this
clinical trial in 2001 and will owe other amounts upon the completion of certain
parts of the trial, with the last payment due upon receipt of the final written
report on the trial. The Company can terminate this agreement up to 60 days
after receipt of this report. After expiration of this ability to terminate, the
Company must issue 25,000 shares of the Company's common stock to Mayo and must
pay milestone payments upon certain regulatory or other events and royalties on
future sales, if any. In addition, the Company paid $60,000 to Mayo related to
the agreement in 2001. The Company's right to continue this agreement was
transferred to Hemispherx. See "Business - General Development of the Business -
Agreement with Hemispherx Biopharma, Inc."
This new approach to cancer therapy being studied at Mayo is referred
to as neo-adjuvant immunotherapy with interferon. The goal of this approach,
which uses a short duration interferon pretreatment, is to stimulate the innate
immune system prior to surgical treatment. This is believed to be particularly
appropriate in light of literature reports of the possible existence of
postoperative anesthesia-induced immunosuppression.
This neo-adjuvant approach is based upon the research in mice with
implanted melanoma. In this study it was found that a short duration treatment
with natural mouse leukocyte interferon prior to surgery significantly increased
the survival rate compared to untreated controls (56% vs. 0%). In addition, at
the end of the study, no evidence of metastatic tumors was found in the
surviving mice. Animals treated with interferon for the same duration
immediately after surgery (adjuvant therapy) did no better than the untreated
controls. It is unknown whether comparable results can be achieved in humans.
Marketing and Distribution. The Company does not have a marketing and
sales force or an agreement with another company to carry out this function. In
June 1998, the Company entered into an agreement with Integrated
Commercialization Solutions, Inc. ("ICS"), a subsidiary of AmerisourceBergen
Corporation, pursuant to which ICS became the sole United States distributor of
ALFERON N Injection. ICS distributes ALFERON N Injection to wholesalers
throughout the United States. The Company does not believe that the loss of any
one wholesaler would have a material adverse effect on the Company's sales or
financial position. ICS also provides clinical and product information,
reimbursement information and services, and management of patient assistant
services. However they do not market the product. At the present time the
Company is dependent upon orders being received from the marketplace and
processed by ICS. Substantially all of the revenues are derived from the sales
of ALFERON N Injection in the United States.
Manufacturing. The purified drug concentrate utilized in the
formulation of ALFERON N Injection is manufactured in the Company's facility
located in New Brunswick, New Jersey, and ALFERON N Injection is formulated and
packaged at a production facility located in McPherson, Kansas and operated by
Abbott. In April 1998 the Company discontinued the first stage of interferon
production because it had produced sufficient inventories of interferon
intermediates to satisfy its commercial needs. The Company has been converting
and intends to continue to convert intermediates to finished product as needed.
See "Management's Discussion and Analysis of Financial Condition and Results of
Operations," "Business - ALFERON N Injection - Clinical Trials for New
Indications," "Business - Governmental Regulation," and "Properties."
Competition. Presently, INTRON A, manufactured by Schering, is the one
other injectable interferon product approved by the FDA for the treatment of
genital warts. INTRON A is made from recombinant alpha interferon. Since the
production of INTRON A is not dependent on a source of human blood cells, it may
be able to be produced in greater volume and at a lower cost than ALFERON N
Injection. Currently, the Company's wholesale price on a per unit basis of
ALFERON N Injection is substantially higher than that of INTRON A. In 1997, 3M
Pharmaceuticals received FDA approval for its immune-response modifier,
Aldara(R), a self-administered topical cream, for the treatment of external
genital and perianal warts. ALFERON N Injection also competes with surgical,
chemical, and other methods of treating genital warts. The Company cannot assess
the impact from products developed by the Company's competitors or advances in
other methods of the treatment of genital warts on the commercial viability of
its product.
If and when the Company obtains approvals for additional indications of
ALFERON N Injection, it expects to compete primarily on the basis of product
performance and price with a number of pharmaceutical companies, both in the
United States and abroad.
In the United States, two recombinant forms of beta interferon, Biogen,
Inc.'s Avonex(R) and Berlex Laboratories' Betaseron(R) as well as Teva
Neuroscience, Inc.'s Copaxone(R), a non-interferon product, have been approved
for the treatment of relapsing-remitting MS. In addition, Immunex Corporation's
Novantrone(R) was approved by the FDA in 2000 for reducing neurological
disability and/or the frequency of clinical relapses in patients with secondary
(chronic) progressive, progressive relapsing or worsening relapsing-remitting
MS.
Many of the Company's potential competitors are among the largest
pharmaceutical companies in the world, are well known to the public and the
medical community, and have substantially greater financial resources and
product development, manufacturing, and marketing capabilities than the Company
or its marketing partners. Therefore, there can be no assurance that, if the
Company is able to obtain regulatory approval of ALFERON N Injection for the
treatment of any additional diseases, it will be able to achieve any significant
penetration into those markets.
Licenses and Royalty Obligations
The Company agreed to pay GP Strategies Corporation ("GP Strategies") a
royalty of $1 million in connection with the acquisition of certain intellectual
property and technology rights from GP Strategies. Such amount is payable if and
when the Company generates income before taxes, limited to 25% of such income
before income taxes per year until the amount is paid in full. To date, the
Company has not generated income before taxes and therefore has not paid
royalties to GP Strategies.
Investments
Metacine, Inc.
On July 28, 2000, the Company acquired for $100,000 an option to purchase
certain securities of Metacine, Inc. ("Metacine"), a company engaged in research
using dendritic cell technology, on the terms set forth below.
On April 9, 2001, the Company exercised its option to acquire an 82% equity
interest in Metacine. Pursuant to the agreement, as amended, the Company
received 700,000 shares of Metacine common stock and a five-year warrant to
purchase, at a price of $12.48 per share, 282,794 shares of Metacine common
stock in exchange for $300,000 in cash, an obligation to pay Metacine $
1,850,000 and $250,000 of services to be rendered by the Company by June 30,
2002. In addition, the Company issued Metacine 2,000,000 shares of the Company's
common stock. The agreement contains certain restrictions on the ability of
Metacine to sell the Company's shares and provides for the Company to make cash
payments ("Deficiency Payments") to Metacine to the extent Metacine has not
received from the sale of the Company's common stock, cumulative net proceeds of
$1,850,000 by September 30, 2002 or $400,000 of net proceeds per quarter
beginning with the period ending September 30, 2001 and $250,000 for the quarter
ending September 30, 2002. On October 4, 2001, the Company made a Deficiency
Payment to Metacine in the amount of $400,000 for the quarter ending September
30, 2001. The Company has not made the remainder of the Deficiency Payments in
the aggregate amount of $1,450,000. If Metacine sells all of the 2,000,000
shares received and the cumulative proceeds from the sales and any Deficiency
Payments are less than $1,850,000, the Company may issue to Metacine additional
shares of common stock at the Company's full discretion. These additional shares
would be treated in the same manner as the original 2,000,000 shares. In the
event that cumulative net proceeds to Metacine from the sale of the Company's
common stock exceed $1,850,000, any Deficiency Payments previously made by the
Company ($400,000 through December 31, 2002) would be repaid to the Company to
the extent these proceeds exceed $1,850,000. All additional proceeds beyond the
$1,850,000 and repayment of Deficiency Payments, if any, would be for the
benefit of Metacine. The Company was required to put in escrow 100,000 Metacine
shares to secure its obligations to render $250,000 of services to Metacine and
462,500 Metacine shares to secure its potential obligations to make Deficiency
Payments. Since the Company has not made $1,450,000 in Deficiency Payments and
has not rendered $250,000 of services to Metcine, Metacine could request 462,500
Metacine shares currently held in escrow to satisfy the Company's past due
obligations.
Although the Company is the majority owner of Metacine, the Company must,
on many matters, vote its shares of Metacine common stock in the same proportion
as votes cast by the minority stockholders of Metacine, except for certain
matters with respect for which the Company has protective rights. In accordance
with EITF Issue No. 96-16, Investor's Accounting for an Investee When the
Investor has a Majority of the Voting Interest but the Minority Shareholder or
Shareholders have Certain Approval or Veto Rights, the minority holders have
substantive participating rights which include controlling the selection,
termination and setting of compensation for Metacine management who are
responsible for implementing policies and procedures, making operating and
capital decisions (including establishing budgets) for Metacine and most other
ordinary operating matters, and therefore, the Company does not control
Metacine. In addition, the Company only has one representative on a board of
directors consisting of three directors. Accordingly, the acquisition is being
accounted for under the equity method.
Of the $2.5 million consideration paid for Metacine, $2,341,418 was
recorded as a charge for the acquisition of in-process research and development
("IPR&D") in 2001. The charge was recorded as the acquisition of IPR&D as
Metacine's primary asset is technology that has not reached technological
feasibility and has no alternative uses. The in-process research and development
expenses relate to a patent portfolio consisting of six issued patents, eight
pending patents and four invention disclosures related to the use of dendritic
cells for the treatment of various diseases. While the patent portfolio, when
viewed as a whole, represented a new approach to the treatment of various
diseases utilizing cell therapy, the six issued patents had no independent
commercial value. While the Company did not engage the services of an
independent appraiser to assess the fair value of the purchased in process
research and development, it considered the following factors: (i) any product
or process utilizing dendritic cells as a treatment for any disease would
regulated by the FDA and therefore would require extensive clinical testing
prior to the time any revenue would be generate from the sale of a product or
process, (ii) the cost of such clinical trials would be in excess of $
50,000,000, (iii) it would take between seven to ten years to complete such
clinical trials, (iv) there could be no assurance that even if Metacine could
obtain the funding required to complete the clinical trials (which was well
beyond Metacine's capability at the time Metacine acquired rights to the patent
portfolio), that the clinical trials would have shown the product or process
tested to be safe and effective. The Company's $1,850,000 obligation to
Metacine, less the $400,000 Deficiency Payment made in October 2001, has been
recorded as a current liability at December 31, 2002 and 2001. The $250,000 of
services to be provided has also been recorded as a current liability. Services
rendered to Metacine to date were immaterial and as such, the liability remained
unchanged at December 31, 2002 and 2001. The investment has been further reduced
to zero at December 31, 2001, by the Company's equity in the loss of Metacine of
$158,582 for the period from April 9, 2001 through December 31, 2001.
On April 1, 2003, the license granted by the University of Pittsburgh
to Metacine covering Metacine's technology was terminated due to non-payment by
Metacine.
Accordingly, the Company's has not reflected its share of its equity in
the losses in Metacine for the years ended December 31, 2002 and 2001 in the
amounts of $274,846 and $290,994, respectively.
The Company is currently in discussions with Metacine with respect to a
full settlement of the Company's obligations to Metacine.
Governmental Regulation
Regulations imposed by U.S. federal, state, and local authorities, as
well as their counterparts in other countries, are a significant factor in the
conduct of the research, development, manufacturing, and marketing activities
for present and proposed products developed by the Company.
The Company's or its licensees' potential products will require
regulatory approval by governmental agencies prior to commercialization. In
particular, human medical products are subject to rigorous pre-clinical and
clinical testing and other approval procedures by the FDA in the United States
and similar health authorities in foreign countries. Various federal and, in
some cases, state statutes and regulations also govern or influence the
manufacturing, safety, labeling, storage, record keeping, and marketing of such
products, including the use, manufacture, storage, handling, and disposal of
hazardous materials and certain waste products. The process of obtaining these
approvals and the subsequent compliance with applicable federal and foreign
statutes and regulations involves a time-consuming process and requires the
expenditure of substantial resources.
The effect of government regulation may be to delay for a considerable
period of time or prevent the marketing of any product that the Company may
develop and/or impose costly procedures on the Company's activities, the result
of which may be to furnish an advantage to the Company's competitors. Any delay
in obtaining or failure to obtain such approvals would adversely affect the
marketing of the Company's products and the ability to earn product revenue.
Before testing of any agents with potential therapeutic value in
healthy human test subjects or patients may begin, stringent government
requirements for pre-clinical data must be satisfied. These data, obtained from
studies in several animal species, as well as from laboratory studies, are
submitted in a Notice of Claimed Investigational Exemption for a New Drug or its
equivalent in countries outside the U.S. where clinical studies are to be
conducted. If the necessary authorizations are received, the Company then
conducts clinical tests of its products on human beings at various unaffiliated
medical centers and institutions. Initial trials (Phase 1) are conducted on a
small number of volunteers to determine whether the drug is safe for human
beings. If the initial trials demonstrate the safety of the product, trials
(Phase 2) are then conducted on patients affected with the disease or condition
under investigation to establish the proper dose and dosing interval. The
findings of these trials are then used to design and implement large-scale
controlled trials (Phase 3) to provide statistical proof of effectiveness and
adequate evidence of safety to meet FDA and/or foreign approval requirements.
The FDA closely monitors the progress of each of the phases of clinical
testing and may, at its discretion, re-evaluate, alter, suspend, or terminate
the testing based on the data which have been accumulated to that point and its
assessment of the risk/benefit ratio to the patient. Estimates of the total time
required for completing clinical testing vary between four and ten years. Upon
successful completion of clinical testing of a new drug, a company typically
submits a New Drug Application ("NDA"), or for biological products such as
Natural Alpha Interferon, a Biological License Application ("BLA"), to the FDA
summarizing the results and observations of the drug during the clinical trials.
Each facility, in which products are produced and packaged, whether
operated by the Company or a third party, must meet the FDA's standards for
current good manufacturing practices and must also be approved prior to
marketing any product produced or packaged in such facility. Any significant
change in the production process that may be commercially required, including
changes in sources of certain raw materials, or any change in the location of
the production facilities will also require FDA approval. To the extent a
portion of the manufacturing process for a product is handled by an entity other
than the Company, the Company must similarly receive FDA approval for the other
entity's participation in the manufacturing process. Abbott formulates and
packages ALFERON N Injection. The Company presently has a biologic establishment
license for the facilities in which it produces ALFERON N Injection, which
includes the facilities in which Abbott formulates and packages ALFERON N
Injection.
Once the manufacture and sale of a product is approved, various FDA
regulations govern the production processes and marketing activities of such
product. A post-marketing testing, surveillance, and reporting program may be
required to monitor the product's usage and effects. Product approvals may be
withdrawn, or other actions may be ordered, if compliance with regulatory
standards is not maintained.
Each individual lot of Natural Alpha Interferon produced must be tested
for compliance with specifications and released for sale by the FDA prior to
distribution in the marketplace. Even after initial FDA marketing approval for a
product has been granted, further studies may be required to provide additional
data on safety or efficacy; to obtain approval for marketing a product as a
treatment for specific diseases other than those for which the product was
originally approved; to change the dosage levels of a product; to support new
safety or efficacy claims for the product; or to support changes in
manufacturing methods, facilities, sources of raw materials, or packaging.
In many markets, effective commercialization also requires inclusion of
the product in national, state, provincial, or institutional formularies or cost
reimbursement systems. The impact of new or changed laws or regulations cannot
be predicted with any accuracy. The Company uses its own staff of regulatory
affairs professionals and outside consultants to enable it to monitor
compliance, not only with FDA laws and regulations, but also with state and
foreign government laws and regulations.
Promotional and educational communications by the Company and its
distributors also are regulated by the FDA and are governed by statutory and
regulatory restrictions and FDA policies regarding the type and extent of data
necessary to support claims that may be made. The Company currently does not
have data adequate to satisfy FDA requirements with respect to potential
comparative claims between Natural Alpha Interferon and competing recombinant
interferon products.
For marketing outside the United States, the Company will also be
subject to foreign regulatory requirements governing human clinical trials,
manufacturing, and marketing approval for drugs and other medical products. The
requirements governing the conduct of clinical trials, product licensing,
pricing, and reimbursement vary widely from country to country.
Under certain circumstances, the Company may be required to obtain FDA
authorization to export products for sale in foreign countries. For instance, in
most cases, the Company may not export products that have not been approved by
the FDA unless it first obtains an export permit from the FDA. However, these
FDA export restrictions generally do not apply if the Company's products are
exported in conformance with their United States approvals or are manufactured
outside the United States. At the present time, the Company does not have any
foreign manufacturing facilities.
Employees
As of May 1, 2003, the Company had 4 employees, 3 of whom work less
than full time. All of such employees are providing services in connection with
the Asset Sale Transaction.
Research and Development
During the years ended December 31, 2002, 2001 and 2000, the Company
expended approximately $1.5 million, $2.3 million and $1.5 million,
respectively, for research and development. Substantially all of these
expenditures were for Company-sponsored research and development programs.
Executive Officers of the Registrant
The following table sets forth the names of the directors and principal
executive officers of the Company as of May 15, 2003, their positions with the
Company, and their principal business experience for the last five years.
Name Age Position
- ---- ---- --------
Samuel H. Ronel, Ph.D 67 Chairman of the Board
Lawrence M. Gordon 49 Chief Executive Officer and a Director
Stanley G. Schutzbank, Ph.D., R.A.C. 58 President and a Director
Donald W. Anderson 53 Controller (Principal Accounting and
Financial Officer) and Secretary
Sheldon L. Glashow 69 Director
Samuel H. Ronel, Ph.D. has been Chairman of the Board since February
1997 and was Vice Chairman of the Board from January 1996 to February 1997 and
President, Chief Executive Officer, and a director of the Company from 1981 to
January 1996. He was responsible for the interferon research and development
program since its inception in 1979. Dr. Ronel joined GP Strategies in 1970 and
served as the Vice President of Research and Development of GP Strategies and as
the President of Hydro Med Sciences, a division of GP Strategies, from 1976 to
September 1996. Dr. Ronel served as President of the Association of
Biotechnology Companies, an international organization representing United
States and foreign biotechnology firms, from 1986-88 and has served as a member
of its Board of Directors until 1993. Dr. Ronel was elected to the Board of
Directors of the Biotechnology Industry Organization from 1993 to 1995 and to
the Governing Body of the Emerging Companies Section from 1993 to 1997. Since
1999 he has been a member of the Technology Advisory Board of the New Jersey
Economic Development Authority. In 2001, Dr. Ronel was named member of the
Advisory Commission to the Biotechnology Research Institute, Montreal, a
National Research Council of Canada institution.
Lawrence M. Gordon has been Chief Executive Officer and a director of
the Company since January 1996, Vice President of the Company from June 1991 to
January 1996, General Counsel of the Company from 1984 to January 1996.
Stanley G. Schutzbank, Ph.D. has been President of the Company since
January 1996, Executive Vice President of the Company from 1981 to January 1996,
and a director of the Company since 1981 and has been associated with the
interferon research and development program since its inception in 1979. He is
involved with all facets of administration and planning of the Company and has
coordinated compliance with FDA regulations governing manufacturing and clinical
testing of interferon, leading to the approval of ALFERON N Injection in 1989.
Dr. Schutzbank joined GP Strategies (previously National Patent Development
Corporation) in 1972 and served as the Corporate Director of Regulatory and
Clinical Affairs from 1976 to September 1996 and as Executive Vice President of
Hydro Med Sciences from 1982 to September 1996. Dr. Schutzbank is a member of
the Regulatory Affairs Professionals Society ("RAPS") and has served as Chairman
of the Regulatory Affairs Certification Board from its inception until 1994. Dr.
Schutzbank received the 1991 Richard E. Greco Regulatory Affairs Professional of
the Year Award for his leadership in developing the United States Regulatory
Affairs Certification Program. In September 1995, Dr. Schutzbank was elected to
serve as President-elect in 1996, President in 1997, and Chairman of the Board
in 1998 of RAPS. In October 2000, Dr. Schutzbank received the Leonard J.
Stauffer Award from RAPS. RAPS gives this award once each year to a Regulatory
Affairs Certified ("RAC") individual who exemplifies outstanding service to the
RAC Program and/or mentoring in the regulatory affairs profession.
Donald W. Anderson has been the Controller of the Company since 1981
and Corporate Secretary of the Company since 1988. He was an officer of various
subsidiaries of GP Strategies from 1976 to September 1996.
Sheldon L. Glashow, Ph.D. has been a director of the Company since 1991. He
has been a director of GP Strategies since 1987, a director of GSE Systems, Inc.
since 1995, and a director of CalCol, Inc. since 1994. Dr. Glashow is the
Higgins Professor of Physics and the Mellon Professor of the Sciences at Harvard
University. He was a Distinguished Professor and visiting Professor of Physics
at Boston University. In 1971, he received the Nobel Prize in Physics.
(d) Financial Information About Foreign and Domestic Operations and Export
Sales
All of the Company's material operations and sales are conducted in the
United States.
Item 2. Properties
The Company's executive offices and its research and production
facilities are located at 783 Jersey Avenue, New Brunswick, New Jersey 08901,
and its telephone number is (732) 249-3250.
The Company owns two freestanding buildings comprising approximately
44,000 square feet that are located in New Brunswick, New Jersey. The Company
uses the facilities for staff offices, manufacturing, quality control and
research activities, and storage. The Company's properties are subject to the
Asset Sales Transactions.
Item 3. Legal Proceedings
The Company is not a party to any legal proceedings.
Item 4. Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of security holders during the
fourth quarter of the fiscal year covered by this report.
PART II
Item 5. Market for the Registrant's Common Stock and Related Stockholder Matters
The Common Stock is traded on the OTC Bulletin Board and is quoted
under the symbol IFSC. The following table sets forth for each period indicated,
the high and low sales prices for the Common Stock as reported on the OTC
Bulletin Board.
2 0 0 2 2 0 0 1
------------ -----------
Quarter High Low High Low
- ------- ---- --- ---- ---
First $0.49 $0.16 $0.97 $0.22
Second 0.22 0.08 0.53 0.24
Third 0.10 0.04 0.44 0.11
Fourth 0.08 0.04 0.52 0.14
As of April 30, 2003, the Company had 472 stockholders of record.
The Company has not paid any dividends on the Common Stock since its
inception and does not contemplate paying dividends on the Common Stock in the
foreseeable future.
Item 6. Selected Financial Data
- --------------------------------
(Thousands of dollars except per share data)
Year Ended December 31,
2002 2001 2000 1999 1998
---- ---- ---- ---- ----
As As As As
Restated Restated Restated Restated
(See Note 4) (See Note 4)
Revenues $ 1,926 $ 1,499 $ 1,069 $ 2,329 $ 2,007
Cost of goods sold and excess/
idle production costs 1,482 1,486 1,456 2,590 6,008
Increase of inventory reserve 3,090
Research and development costs, net 1,514 2,286 1,533 3,060 8,655
General and administrative expense 1,818 2,647 2,306 2,315 4,570
Loss from operations* (2,888) (7,262) (4,226) (5,636) (20,316)
Interest income (expense and
financing costs), net (379) 17 74 (530) 253
Gain on sale of state net
operating loss carryovers 528 969 1,484 2,349
Net loss* (2,738) (6,435) (2,669) (3,818) (20,800)
Basic and diluted loss per share (.13) (.33) (.22) (.75) (6.50)
Dividends NONE NONE NONE NONE NONE
- ----------------------------------
*The Company has suffered recurring losses from operations, has an accumulated
deficit, a working capital deficiency and has limited liquid resources that
raise substantial doubt about its ability to continue as a going concern (see
Note 3 to the Consolidated Financial Statements).
December 31,
2002 2001 2000 1999 1998
------------------------------------------------
As As As As
Restated Restated Restated Restated
(See Note 4)(See Note 4)
Total assets $2,276 $3,685 $8,266 $5,490 $6,599
Working capital (deficiency) (5,138) (3,413) 2,311 (2,863) (1,889)
Long-term debt 500
Stockholders' equity (deficiency) (3,324) (1,164) 5,121 (209) 2,103
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations
Since 1981, the Company was engaged in the research and development of
pharmaceutical products containing Natural Alpha Interferon. The Company has
experienced significant operating losses since its inception. The Company
received FDA approval in 1989 to market ALFERON N Injection in the United States
for the treatment of certain types of genital warts.
Agreement with Hemispherx Biopharma, Inc. ("HEB")
On March 11, 2003, the Company executed the Asset Sale Transactions
with HEB to sell certain assets of ISI.
In the First Asset Sale Agreement, ISI sold all of its inventory
related to ALFERON N Injection(R) and granted a three-year license for the
production, manufacture, use, marketing and sale of the product in the United
States.
For these assets, ISI:
(i) received 424,528 shares of HEB common stock (the "Common Stock")
(these shares, along with other shares described below as having
a guaranteed value, are sometimes referred to as the "Guaranteed
Shares") which had a Market Value (as defined in the First Asset
Sale Agreement) of $675,000 and a guaranteed value of $675,000;
(ii) received an additional 62,500 shares of Common Stock without a
guaranteed value; and
(iii)will receive a royalty equal to 6% of the net sales of the
product.
ISI will receive a service fee for providing certain transitional
services. In addition, HEB will assume ISI payables and certain other
obligations related to the Product. This Agreement obligates HEB to register the
Common Stock issued to ISI, sets periodic limits on the number of shares ISI may
sell and requires HEB to pay ISI an amount equal to the product received by
multiplying (i) the number of Guaranteed Shares remaining unsold on March 11,
2005 and (ii) $ 1.59. The remaining Guaranteed Shares will then be returned to
HEB.
In the Second Asset Sale Agreement, ISI has agreed to sell, subject to
certain approvals, to HEB all of its rights to natural alpha interferon, (the
"Product") and other assets related to the Product including, but not limited
to, real estate and machinery. For these assets, ISI will:
(i) receive 424,528 shares of HEB Common Stock which has a Market
Value (as defined in the Second Asset Sale Agreement) of $675,000
and a guaranteed value of $675,000;
(ii) receive an additional 62,500 shares of HEB Common Stock without a
guaranteed value; and
(iii)receive a royalty equal to 6% of the net sales of any products
containing natural alpha interferon sold by HEB (or a Marketing
Partner, as defined in the Second Asset Sale Agreement).
In addition, HEB will be required to satisfy three obligations of ISI
which aggregate approximately $2,300,000. HEB will be obligated to pay certain
ongoing expenses related to ISI's operations prior to the closing of the Second
Asset Sale Agreement.
The Second Asset Sale Agreement obligates HEB to register the Common
Stock to be issued, sets periodic limits on the number of these shares that may
be sold and requires HEB to pay ISI an amount equal to the product received by
multiplying (i) the number of Guaranteed Shares remaining unsold on the date
which is two years after the closing date of the Second Asset Sale Agreement and
(ii) $1.59. The remaining Guaranteed Shares will then be returned to HEB.
The purchase price for the assets was determined by negotiation between
HEB and ISI.
The foregoing descriptions of the Asset Sale Transactions, the First
Asset Sale Agreement and the Second Asset Sale Agreement are qualified in their
entirety by reference to the full text of the First Asset Sale Agreement, the
Second Asset Sale Agreement, which are filed as Exhibits 2.1 and 2.2 to the
Current Report on Form 8-K, dated March 18, 2003, and incorporated herein by
reference.
Liquidity and Capital Resources
During the year ended December 31, 2002, the Company generated
$1,926,466 in revenues from the sale of ALFERON N Injection and received
$528,276 from the sale of the Company's New Jersey net operating loss
carryovers. In addition, the Company completed a private placement of $500,000
of convertible notes to accredited investors. Each note is convertible into the
Company's common stock at a price of $.05 per share (subject to adjustment to
70% of the market price of the Company's common stock under certain
circumstances) and bears interest at the rate of 10% per annum. $250,000 of the
convertible notes was due January 31, 2003 and the other $250,000 of the
convertible notes are due December 31, 2003. For each $100,000 principal amount
of notes issued, the investors received warrants to purchase an additional 10.2
million shares of the Company's common stock exercisable at $.01 per share. The
transaction is subject to approval by the shareholders of the Company. In the
event that shareholder approval is not obtained, the convertible noteholders
could exercise their rights and call a default making the convertible notes
immediately due and payable. All of the above accounted for substantially all of
the Company's funding in 2002. As of June 12, 2003, the Company had an aggregate
of approximately $195,000 in cash and cash equivalents. Until utilized, such
cash and cash equivalents are being invested principally in short-term
interest-bearing investments. At the current time, the Company is focusing its
efforts on completing the Asset Sale Transactions and evaluating new
opportunities for the Company.
Based on the Company's sale to HEB, estimates of revenue, expenses, and
the timing of repayment of creditors, management believes that the cash
presently available will be sufficient to enable the Company to continue
operations until the third quarter of 2003. However, actual results may differ
materially from such estimate, and no assurance can be given that additional
funding will not be required sooner than anticipated or that such additional
funding will be available when needed or on terms acceptable to the Company.
Insufficient funds will require the Company to scale back or terminate
operations. The independent auditors' report, dated June 10, 2003 on the
Company's consolidated financial statements as of and for the years ended
December 31, 2002 and 2001 included an explanatory paragraph that states that
the Company has experienced a significant loss from operations, has a capital
deficiency, and a negative working capital position. These factors raise
substantial doubt about its ability to continue as a going concern.
On April 9, 2001, the Company exercised its option to acquire a
substantial equity interest in Metacine, Inc. Pursuant to the agreement, as
amended, the Company received 700,000 shares of Metacine common stock and a
five-year warrant to purchase, at a price of $12.48 per share, 282,794 shares of
Metacine common stock in exchange for $300,000 in cash, $250,000 of services to
be rendered by the Company by June 30, 2002 and 2,000,000 shares of the
Company's common stock. The agreement contains certain restrictions on the
ability of Metacine to sell the Company's shares and provides for cash payments
("Deficiency Payments") by the Company to Metacine to the extent Metacine has
not received, from the sale of the Company's common stock, cumulative net
proceeds of $1,850,000 by September 30, 2002 or $400,000 of net proceeds per
quarter beginning with the period ending September 30, 2001 and $250,000 for the
quarter ending September 30, 2002. In October 2001, the Company made a
Deficiency Payment to Metacine in the amount of $400,000 for the quarter ending
September 30, 2001. The Company has not, as yet, made the remainder of the
Deficiency Payments in the aggregate amount of $1,450,000. The Company is
currently discussing various options regarding the balance of the Deficiency
Payments with Metacine. In the event that and to the extent that cumulative net
proceeds to Metacine from the sale of the Company's common stock exceed
$1,850,000, any Deficiency Payments previously made by the Company would be
repaid to the Company.
The Company has participated in the State of New Jersey's corporation
business tax benefit certificate transfer program (the "Program"), which allows
certain high technology and biotechnology companies to transfer unused New
Jersey net operating loss carryovers to other New Jersey corporation business
taxpayers. During 1999, the Company submitted an application to the New Jersey
Economic Development Authority (the "EDA") to participate in the Program and the
application was approved. The EDA then issued a certificate certifying the
Company's eligibility to participate in the Program and the amount of New Jersey
net operating loss carryovers the Company has available to transfer. Since New
Jersey law provides that net operating losses can be carried over for up to
seven years, the Company may be able to transfer its New Jersey net operating
losses from the last seven years. The Company estimated that, as of January 1,
1999, it had approximately $85 million of unused New Jersey net operating loss
carryovers available for transfer under the Program. The Program requires that a
purchaser pay at least 75% of the amount of the surrendered tax benefit.
During December 2002, 2001, and 2000, the Company completed the sale of
approximately $6.5 million, $12 million, and $19 million of its New Jersey tax
loss carryovers and received $0.53 million, $0.97 million, and $1.48 million,
which were recorded as a gain on sale of state net operating loss carryovers on
the Company's Consolidated Statement of Operations in 2002, 2001, and 2000,
respectively. If the Company is eligible, in June 2003, the Company will submit
an application to sell an additional approximately $2.0 million of tax benefits
(calculated by multiplying the Company's unused New Jersey net operating loss
carryovers through December 31, 2000 of approximately $22.6 million by 9%). The
actual amount of such tax benefits the Company may sell will depend upon the
allocation among qualifying companies of an annual pool established by the State
of New Jersey. The allocated pool for fiscal year 2003 and future years is $40
million per year.
The Company obtained human white blood cells used in the manufacture of
ALFERON N Injection from several sources, including the Red Cross pursuant to a
supply agreement dated April 1, 1997 (the "Supply Agreement"). The Company will
not need to purchase more human white blood cells until such time as production
of crude alpha interferon is resumed. Under the terms of the Supply Agreement,
the Company was obligated to purchase a minimum amount of human white blood
cells each month through March 1999 (the "Minimum Purchase Commitment"), with an
aggregate Minimum Purchase Commitment during the period from April 1998 through
March 1999 in excess of $3,000,000. As of November 23, 1998, the Company owed
the Red Cross approximately $1.46 million plus interest at the rate of 6% per
annum accruing from April 1, 1998 (the "Red Cross Liability") for white blood
cells purchased pursuant to the Supply Agreement.
In an agreement dated November 23, 1998, the Company agreed to grant
the Red Cross a security interest in certain assets to secure the Red Cross
Liability and to issue to the Red Cross 300,000 shares of common stock and
additional shares at some future date as requested by the Red Cross to satisfy
any remaining amount of the Red Cross Liability. The Red Cross agreed that any
net proceeds received by it upon sale of such shares would be applied against
the Red Cross Liability and that at such time as the Red Cross Liability was
paid in full, the Minimum Purchase Commitment would be deleted effective April
1, 1998 and any then existing breaches of the Minimum Purchase Commitment would
be waived. In January 1999 the Company granted the Red Cross a security interest
(the "Security Interest") in, among other things, the Company's real estate,
equipment inventory, receivables, and New Jersey net operating loss carryovers
to secure repayment of the Red Cross Liability, and the Red Cross agreed to
forbear from exercising its rights under the Supply Agreement, including with
respect to collecting the Red Cross Liability, until June 30, 1999 (which was
subsequently extended until December 31, 1999). On December 29, 1999, the
Company, the Red Cross and GP Strategies entered into an agreement pursuant to
which the Red Cross agreed that until September 30, 2000 it would forbear from
exercising its rights under (i) the Supply Agreement, including with respect to
collecting the Red Cross Liability, and (ii) the Security Interest. In
connection with the Asset Sale Transactions, the Company, HEB and the Red Cross
entered into a similar agreement pursuant to which the Red Cross agreed to
forbear from exercising its rights until May 31, 2003 and the Red Cross agreed
to accept HEB common stock with a guaranteed value of $500,000 in full
settlement of all of the Company's obligations to the Red Cross. Under the terms
of such agreement, if HEB does not make such payment, the Red Cross has the
right to sell the Company's real estate.
Pursuant to an agreement dated March 25, 1999, GP Strategies loaned the
Company $500,000 (the "GP Strategies Debt"). In return, the Company agreed to
grant GP Strategies (i) a first mortgage on the Company's real estate, (ii) a
two-year option (which has expired) to purchase the Company's real estate,
provided that the Company has terminated its operations and the Red Cross
Liability has been repaid, and (iii) a two-year right of first refusal (which
has expired) in the event the Company desires to sell its real estate. In
addition, the Company agreed to issue GP Strategies 500,000 shares of common
stock (the "GP Shares") and a five-year warrant (the "GP Warrant") to purchase
500,000 shares of common stock at a price of $1 per share. The common stock and
warrants issued to GP Strategies were valued at $500,000 and recorded as a
financing cost and amortized over the original period of the GP Strategies Debt
in 1999. Pursuant to the agreement, the Company issued a note to GP Strategies
representing the GP Strategies Debt, which note was due on September 30, 1999
and bears interest, payable at maturity, at the rate of 6% per annum. In
addition, at that time the Company negotiated a subordination agreement with the
Red Cross pursuant to which the Red Cross agreed that its lien on the Company's
real estate is subordinate to GP Strategies' lien. On March 27, 2000, the
Company and GP Strategies entered into an agreement pursuant to which (i) the GP
Strategies Debt was extended until June 30, 2001, and (ii) the Management
Agreement between the Company and GP Strategies was terminated and all
intercompany accounts between the Company and GP Strategies (other than the GP
Strategies Debt) in the amount of approximately $130,000 were discharged which
was recorded as a credit to capital in excess of par value. On August 23, 2001,
the Company and GP Strategies entered into an agreement pursuant to which the GP
Strategies Debt was extended to March 15, 2002. During 2001, the Company paid GP
Strategies $100,000 to reduce the GP Strategies Debt. In addition, in January
2002, the Company paid GP Strategies $100,000 to further reduce the GP
Strategies Debt. In connection with the Asset Sale Transactions, the Company,
HEB and GP Strategies entered into a similar agreement pursuant to which GP
Strategies agreed to forbear from exercising its rights until May 31, 2003 and
GP Strategies agreed to accept HEB common stock with a guaranteed value of
$425,000 in full settlement of all of the Company's obligations to GP
Strategies. Under the terms of such agreement, if HEB does not make such
payment, GP Strategies has the right to sell the Company's real estate.
The Company's common stock now trades on the OTC Bulletin Board, which
may have a material adverse effect on the ability of the Company to finance its
operations and on the liquidity of the common stock.
Critical Accounting Policies
Inventory reserves - The Company provides inventory reserves based on
the anticipated near-term projections of product to be sold or utilized in
clinical trials, giving consideration to historical sales levels. These
estimates could be materially different from actual usage.
Commitments
As discussed above, the Company is obligated to make Deficiency
Payments to Metacine for which the Company owes an aggregate amount of
$1,450,000. The Company also has not rendered $250,000 of services to Metacine.
The Company is currently in discussions with Metacine with respect to a full
settlement of the Company's obligations to Metacine. Also as discussed above,
the Company's note payable to GP Strategies of approximately $414,000 was due
March 15, 2002 and has not yet been paid. In connection with the Asset Sale
Transactions, the Company, HEB and GP Strategies entered into a similar
agreement pursuant to which GP Strategies agreed to forbear from exercising its
rights until May 31, 2003 and GP Strategies agreed to accept HEB common stock
with a guaranteed value of $425,000 in full settlement of all of the Company's
obligations to GP Strategies.
As consideration for the transfer to the Company of certain licenses,
rights and assets upon the formation of the Company by GP Strategies, the
Company agreed to pay GP Strategies royalties of $1,000,000, but such payments
will be made only with respect to those years in which the Company has income
before income taxes, and will be limited to 25% of such income. Through December
31, 2002, the Company has not generated income before taxes and therefore has
not accrued or paid royalties to GP Strategies.
Major Research and Development Projects
Cancer
During the year ended December 31, 2002, the Company incurred $101,565
in connection with its collaboration with the Mayo Foundation for Medical
Education and Research pursuant to which the Company is funding a clinical trial
entitled "Identification of an Immunostimulatory Dose of Natural Interferon
(Phase A) and Its Impact on Clinical Outcome (Phase B) in Patients with
Melanoma. The Company estimates that the time to complete this trial will be at
least two years. However, because of the need to recruit patients who meet
certain limited criteria to complete the trial, it is very difficult to
accurately estimate the date the trial will be completed. Under the terms of the
Company's agreement with Mayo, the cost to complete this clinical trial is
approximately $200,000. Under the terms of the Company's agreement with
Hemispherx (see "Business - General Development of the Business - Agreement with
Hemispherx Biopharma, Inc.") the Company's right to continue this agreement and
the obligation owed to Mayo was transferred to Hemispherx.
Multiple Sclerosis
During the year ended December 31, 2001, the Company incurred
approximately $91,594 funding a study which entailed a retrospective review of
multiple brain magnetic resonance imaging (MRI) scans to assess MS brain lesion
burden. The study compared the scans of 40 MS patients treated with interferon
alfa-n3 (ALFERON N Injection) as well as 40 MS patients treated with interferon
beta-1b (Betaseron(R)), both before therapy and at least six months after
initiation of therapy. A control group of 39 untreated MS patient scans were
also evaluated with an initial MRI scan at baseline and a second MRI obtained at
least six months after the baseline examination. On the 238 scans evaluated (119
patients) only lesions of larger than 5 mm3 were measured to avoid inclusion of
potential non-MS lesions and assure accuracy of measurement. All scans were
reviewed by consensus of two experienced neuroradiologists who were blinded to
all identifiers, including name, date, order of scans, and clinical status of
the patient.
The study data showed a reduction in the volume of T2-weighted MS brain
lesions in both the interferon alfa-n3 treated group (-10%) and the interferon
beta-1b treated group (-7%), as compared to increased lesion volume in the
untreated control group (+12%).
Changes in disability scores amongst the groups were also
retrospectively reviewed, based on the extended disability status scale (EDSS).
Only patients with EDSS scores recorded both at baseline and after at least 12
months were evaluated, which included 38 interferon alfa-n3 treated patients, 31
interferon beta-1b treated patients, and 33 untreated patients. The results
showed the mean absolute change in EDSS scores from baseline to be -1.07 for
interferon alfa-n3 treated patients and -0.16 for interferon beta-1b treated
patients after 12 months, as compared to +0.80 for untreated patients (negative
changes reflect decreased disability scores, positive change reflects increased
disability scores). The scale of EDSS scores ranges from 0 for a normal
neurological examination to a score of 10 for death due to MS.
Under the terms of the Company's agreement with Hemispherx (see
"Business - General Development of the Business - Agreement with Hemispherx
Biopharma, Inc.") the Company's right to continue work utilizing ALFERON N
Injection for the treatment of multiple sclerosis was licensed to Hemispherx.
Results of Operations
Year Ended December 31, 2002 Versus Year Ended December 31, 2001
For the year ended December 31, 2002 (the "2002 Period") and 2001 (the
"2001 Period"), the Company had revenues from the sale of ALFERON N Injection of
$1,926,466 and $1,498,603, respectively. During the first quarter of 2002, the
Company notified its customers of a price increase for ALFERON N Injection. As a
result, several wholesalers purchased above-normal quantities of ALFERON N
Injection ahead of the price increase. In addition, during the third quarter of
2002, the Company offered price concessions to its largest customers in an
attempt to raise cash from the sale of ALFERON N Injection, which resulted in
greater than normal sales in the 2002 period.
In the 2002 Period, the Company sold, through its distributor, to
wholesalers and other customers in the United States 15,012 vials of ALFERON N
Injection, compared to 11,296 vials sold by the Company during the 2001 Period.
In addition, foreign sales of ALFERON N Injection were zero vials and 61 vials
for the 2002 and 2001 Periods, respectively.
Cost of goods sold and excess/idle production costs totaled $1,482,006
and $1,485,962 for the 2002 and 2001 Periods, respectively. Excess/idle
production costs in the 2002 and 2001 Periods represented fixed production
costs, which were incurred after production of ALFERON N Injection was
discontinued in April 1998. Excess/idle production costs were slightly lower
during the 2002 Period as compared to the 2001 Period.
Research and development expenses during the 2002 Period of $1,514,286
decreased by $772,014 from $2,286,300 for the 2001 Period, due to decreases in
both external research payments and internal research costs.
General and administrative expenses for the 2002 Period were $1,818,194
as compared to $2,646,734 for the 2001 Period. The decrease of $828,540 was
principally due to decreases in payroll, consulting and public relations
expenses.
The Company recorded $2,341,418 as acquisition of in-process research
and development expenses related to its investment in Metacine for the 2001
Period as Metacine's primary asset is technology which has not reached
technological feasibility and has no alternative uses. See Note 7 of Notes to
Consolidated Financial Statements.
Interest income for the 2002 Period was $7,122 as compared to $108,351
for the 2001 Period. The decrease of $101,229 was due to less funds available
for investment in the 2002 Period.
Interest expense for the 2002 Period was $385,775 as compared to
$91,469 for the 2001 Period. The increase of $294,306 was primarily due to the
interest, including amortization of debt discount, on the convertible notes
payable.
Equity in loss of Metacine for the 2001 Period was $158,582 and
represents the Company's equity in loss of Metacine for the period from April 9,
2001 to December 31, 2001.
During 2002 and 2001, the Company completed the sale of a portion of
its New Jersey tax net operating loss carryforwards and recorded a gain on such
sale amounting to $528,276 and $968,553, which is recorded as an income tax
benefit in the 2002 and 2001 Periods, respectively.
As a result of the foregoing, the Company incurred net losses of
$2,738,397 and $6,434,958 for the 2002 and 2001 Periods, respectively.
Year Ended December 31, 2001 versus Year Ended December 31, 2000
For the year ended December 31, 2001 (the "2001 Period") and 2000 (the
"2000 Period"), the Company had revenues from the sale of ALFERON N Injection of
$1,498,603 and $1,067,471, respectively. In 1999, the Company offered price
concessions to its largest customers in an attempt to raise cash from the sale
of ALFERON N Injection, which resulted in lower than normal sales in the 2000
Period. This was due to the fact that such customers were selling out of their
inventory of ALFERON N Injection (rather than purchasing ALFERON N Injection
from the Company).
In the 2001 Period, the Company sold, through its distributor, to
wholesalers and other customers in the United States 11,296 vials of ALFERON N
Injection, compared to 7,946 vials sold by the Company during the 2000 Period.
In addition, foreign sales of ALFERON N Injection were 61 vials and 132 vials
for the 2001 and 2000 Periods, respectively.
Cost of goods sold and excess/idle production costs totaled $1,485,962
and $1,455,929 for the 2001 Period and 2000 Period, respectively. Excess/idle
production costs in the 2001 and 2000 Periods represented fixed production
costs, which were incurred after production of ALFERON N Injection was
discontinued in April 1998. Excess/idle production costs were slightly lower
during the 2001 Period as compared to the 2000 Period.
Research and development expenses during the 2001 Period of $2,286,300
increased by $752,976 from $1,533,324 for the 2000 Period, principally because
during the second quarter of 2000, the Company settled amounts owed on various
research related liabilities at a savings to the Company of approximately
$457,000. Such amount was credited against research and development expenses.
The Company also incurred increases in payroll and research costs during the
2001 Period, as compared to the 2000 Period.
General and administrative expenses for the 2001 Period were $2,646,734
as compared to $2,306,146 for the 2000 Period. The increase of $340,588 was
principally due to increases in payroll and other operating expenses.
The Company recorded $2,341,418 as acquisition of in-process research
and development expense related to its investment in Metacine for the 2001
Period as Metacine's primary asset is technology which has not reached
technological feasibility and has no alternative uses. The in-process research
and development expenses relate to research utilizing dendritic cells for the
treatment of various diseases.
Interest income for the 2001 Period and 2000 Period was $108,351 and
$161,835, respectively. The decrease of $53,484 was due to less funds available
for investment in the 2001 Period.
Interest expense for the 2001 Period and 2000 Period was $91,469 and
$87,873, respectively, and represents interest expense accrued on the Red Cross
Liability and GP Strategies Debt.
Equity in loss of Metacine for the 2001 Period was $158,582 and
represents the Company's equity in loss of Metacine for the period from April 9,
2001 to December 31, 2001.
During 2001 and 2000, the Company completed the sale of a portion of
its New Jersey tax net operating loss carryforwards and recorded a gain on such
sale amounting to $968,553 and $1,483,861, which is recorded as an income tax
benefit in the 2001 and 2000 Periods, respectively.
As a result of the foregoing, the Company incurred net losses of
$6,434,958 and $2,668,663 for the 2001 Period and 2000 Period, respectively.
Recently Issued Accounting Standards
In June 2001, the FASB issued SFAS No. 141, Business Combinations, ("SFAS
No. 141") and SFAS No. 142, Goodwill and Other Intangible Assets ("SFAS No.
142"). SFAS No. 141 requires that the purchase method of accounting be used for
all business combinations. SFAS No. 141 specifies criteria that intangible
assets acquired in a business combination must meet to be recognized and
reported separately from goodwill. SFAS No. 142 requires that goodwill and
intangible assets with indefinite useful lives no longer be amortized, but
instead tested for impairment at least annually in accordance with the
provisions of SFAS No. 142. SFAS No. 142 also requires that intangible assets
with estimable useful lives be amortized over their respective estimated useful
lives to their estimated residual values, and reviewed for impairment in
accordance with SFAS No. 121 and subsequently, SFAS No. 144 after its adoption.
The Company adopted the provisions of SFAS No. 141 as of July 1, 2001, and
SFAS No. 142 as of January 1, 2002.
Upon adoption of SFAS No. 142, the Company was required to reassess the
useful lives and residual values of all intangible assets acquired, and make any
necessary amortization period adjustments by the end of the first interim period
after adoption. If an intangible asset was identified as having an indefinite
useful life, the Company would be required to test the intangible asset for
impairment in accordance with the provisions of SFAS No. 142 within the first
interim period. Impairment is measured as the excess of carrying value over the
fair value of an intangible asset with an indefinite life. Any impairment loss
would be measured as of the date of adoption and recognized as the cumulative
effect of a change in accounting principle in the first interim period.
As of the date of adoption of SFAS No. 142, the Company does not have
any goodwill and has unamortized identifiable intangible assets of approximately
$160,000, all of which is subject to the transition provisions of SFAS No. 142.
In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or
Disposal of Long-Lived Assets ("SFAS No. 144"). SFAS No. 144 addresses financial
accounting and reporting for the impairment or disposal of long-lived assets.
This Statement requires that long-lived assets be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Recoverability of assets to be held and used is
measured by a comparison of the carrying amount of an asset to future net cash
flows expected to be generated by the asset. If the carrying amount of an asset
exceeds its estimated future cash flows, an impairment charge is recognized by
the amount by which the carrying amount of the asset exceeds the fair value of
the asset. SFAS No. 144 requires companies to separately report discontinued
operations and extends that reporting to a component of an entity that either
has been disposed of (by sale, abandonment, or in a distribution to owners) or
is classified as held for sale. Assets to be disposed of are reported at the
lower of the carrying amount or fair value less costs to sell. The Company
adopted SFAS No. 144 on January 1, 2002.
In April 2002, the FASB issued SFAS No. 145, "Rescission of FAS
Statements 4, 44 and 64, Amendment of FAS Statement 13 and Technical
Corrections." SFAS No. 145 eliminates Statement 4 (and Statement 64, as it
amends Statement 4), which required gains and losses from extinguishment of debt
to be aggregated and, if material, classified as an extraordinary item, and
thus, also the exception to applying Opinion 30 is eliminated as well. This
statement is effective for fiscal years beginning after May 2002 for the
provisions related to the rescission of Statements 4 and 64 and for all
transactions entered into beginning May 2002 for the provision related to the
amendment of Statement 13. The Company does not expect that the adoption of SFAS
No. 145 will have a material impact on its results of operations or financial
position.
In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs
associated with Exit or Disposal Activities." SFAS No. 146 requires recording
costs associated with exit or disposal activities at their fair values when a
liability has been incurred. Under previous guidance, certain exit costs were
accrued upon management's commitment to an exit plan. The Company is required to
adopt SFAS No. 146 on January 1, 2003. The Company does not expect the adoption
of SFAS No. 146 will have a material impact on its results of operations or
financial position.
In December 2002, the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation - Transition and Disclosure," an amendment to SFAS No.
123, "Accounting for Stock-Based Compensation." Provisions of this statement
provide two additional alternative transition methods: modified prospective
method and retroactive restatement method, for an entity that voluntary changes
to the fair value based method of accounting for stock-based employee
compensation. The statement eliminates the use of the original SFAS No. 123
prospective method of transition alternative for those entities that change to
the fair value based method in fiscal years beginning after December 15, 2003.
It also amends the disclosure provisions of SFAS No. 123 to require prominent
annual disclosure about the effects on reported net income in the Summary of
Significant Accounting Policies and also requires disclosure about these effects
in interim financial statements. These provisions are effective for financial
statements for fiscal years ending after December 15, 2002. Accordingly, the
Company adopted the applicable disclosure requirements of this statement for
year-end reporting. The transition provisions of this statement apply upon the
adoption of the SFAS No. 123 fair value based method. The Company did not change
its method of accounting for employee stock-based compensation from the
intrinsic method to the fair value based alternative.
Forward-Looking Statements
This report contains certain forward-looking statements reflecting
management's current views with respect to future events and financial
performance. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those in
the forward-looking statements, including, but not limited to, the risk that the
Company will run out of cash; uncertainty of obtaining additional funding for
the Company; uncertainty of obtaining United States regulatory approvals for the
additional uses under development for the Company's FDA-approved product and
foreign regulatory approvals if sought and if such approvals are obtained,
uncertainty of the successful commercial development of such product;
substantial competition from companies with substantially greater resources than
the Company in the Company's present and potential businesses; no guaranteed
source of required materials for the Company's product; dependence on certain
contractors to manufacture or distribute the Company's product; potential
adverse side effects from the use of the Company's product; potential patent
infringement claims against the Company; possible inability of the Company to
protect its technology; limited production experience of the Company, risk of
product liability; and risk of loss of key management personnel, all of which
are difficult to predict and many of which are beyond the control of the
Company.
Item 7A. Quantitative and Qualitative Disclosure About Market Risk
Not applicable.
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page
Independent Auditors' Report 21
Financial Statements:
Consolidated Balance Sheets - December 31, 2002 and 2001 22
Consolidated Statements of Operations - Years ended
December 31, 2002, 2001 and 2000 23
Consolidated Statements of Changes in Stockholders'
Equity Capital Deficiency - Years ended December 31, 2002, 2001 and 2000 24
Consolidated Statements of Cash Flows - Years ended
December 31, 2002, 2001 and 2000 25
Notes to Consolidated Financial Statements 26
Schedule II - Valuation and Qualifying Accounts 51
INDEPENDENT AUDITOR'S REPORT
The Board of Directors and Stockholders
Interferon Sciences, Inc.
We have audited the accompanying consolidated balance sheets of
Interferon Sciences, Inc. and subsidiary as of December 31, 2002 and 2001 and
the related consolidated statements of operations, changes in stockholders'
equity capital deficiency and cash flows for each of the years in the three-year
period ended December 31, 2002. These consolidated financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits.
We conducted our audit in accordance with auditing standards generally
accepted in the United States of America. These standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the consolidated financial position of
Interferon Sciences, Inc. and subsidiary as of December 31, 2002 and 2001 and
the consolidated results of their operations and their consolidated cash flows
for each of the years in the three-year period ended December 31, 2002, in
conformity with accounting principles generally accepted in the United States of
America.
The accompanying financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note 3 to the
financial statements, the Company has experienced a significant net losses in
each of the years in the three-year period ended December 31, 2002 and at
December 31, 2002, has a capital deficiency and a negative working capital
position. These factors raise substantial doubt about its ability to continue as
a going concern. Management's plans in regard to these matters are also
described in Note 3. The consolidated financial statements do not include any
adjustments that might result from the outcome of this uncertainty.
In connection with our audit of the financial statements referred to
above, we audited Schedule II - Valuation and Qualifying Accounts for 2002. In
our opinion, this schedule, when considered in relation to the financial
statements taken as a whole, presents fairly, in all material respects, the
information stated therein.
Eisner LLP
New York, New York
June 10, 2003
INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
December 31,
2002 2001
---- ----
As Restated
(See Note 4)
ASSETS
Current assets
Cash and cash equivalents $ 378,663 $ 1,184,889
Accounts and other receivables 42,739 123,389
Inventories, net of reserves of $4,678,659
and $5,538,413, respectively 28,489 109,913
Prepaid expenses and other current assets 12,179 17,608
------------ ------------
Total current assets 462,070 1,435,799
------------- ------------
Property, plant and equipment, at cost
Land 140,650 140,650
Buildings and improvements 7,793,242 7,793,242
Equipment 4,920,942 4,920,942
-------------- ------------
12,854,834 12,854,834
Less accumulated depreciation (11,173,264) (10,776,342)
------------ ------------
1,681,570 2,078,492
------------ ------------
Patent costs, net of accumulated amortization
of $388,974 and $360,819 132,187 160,342
Other assets 100 10,100
------------ ------------
$ 2,275,927 3,684,733
============ ============
LIABILITIES AND CAPITAL DEFICIENCY
Current liabilities
Accounts payable $ 1,387,462 963,323
Accrued expenses 414,262 350,548
Due to American Red Cross 1,402,870 1,339,338
ISI stock subject to resale agreement
and in-kind services due Metacine 1,700,000 1,700,000
Note payable and amount due GP Strategies 413,745 495,745
Convertible Notes payable, net of debt discount 281,863
------------- -------------
Total current liabilities 5,600,202 4,848,954
------------- -------------
Commitments
Capital deficiency
Preferred stock, par value $.01 per share; authorized - 5,000,000 shares; none
issued and outstanding
Common stock, par value $.01 per share; authorized - 55,000,000 shares; issued
and outstanding- 21,030,405 and 20,308,031
shares, respectively 210,304 203,080
Capital in excess of par value 136,810,618 136,239,499
Accumulated deficit (140,345,197) (137,606,800)
-------------- -------------
Total capital deficiency (3,324,275) (1,164,221)
-------------- -------------
$ 2,275,927 3,684,733
============= =============
The accompanying notes are an integral part of these consolidated financial
statements.
INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31,
2002 2001 2000
-------- -------- -------
As Restated As Restated
(See Note 4) (See Note 4)
Revenues
ALFERON N Injection $ 1,926,466 $ 1,498,603 $ 1,067,471
Research products and other revenues 1,442
------------ ------------ -----------
Total revenues 1,926,466 1,498,603 1,068,913
------------ ------------ -----------
Costs and expenses
Cost of goods sold and excess/idle
production costs 1,482,006 1,485,962 1,455,929
Research and development 1,514,286 2,286,300 1,533,324
General and administrative 1,818,194 2,646,734 2,306,146
Acquisition of in-process technology 2,341,418
------------ ------------ -----------
Total costs and expenses 4,814,486 8,760,414 5,295,399
------------ ------------ -----------
Loss from operations (2,888,020) (7,261,811) (4,226,486)
Interest income 7,122 108,351 161,835
Interest expense (385,775) (91,469) (87,873)
Equity in loss of Metacine (158,582)
----------- ------------ -----------
Loss before income tax benefit (3,266,673) (7,403,511) (4,152,524)
Income tax benefit:
Gain on sale of state net operating loss
carryovers 528,276 968,553 1,483,861
------------- ------------ -----------
Net loss $ (2,738,397) $ (6,434,958) $ (2,668,663)
============= ============ ===========
Basic and diluted net loss per share $ (.13) $ (.33) $ (.22)
============= ============ ===========
Weighted average number of
shares outstanding 20,575,948 19,576,312 12,097,252
============= ============= ============
The accompanying notes are an integral part of these consolidated financial
statements.
INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY CAPITAL DEFICIENCY
Total
Capital in stockholders'
Common stock excess of Accumulated Settlement equity
Shares Amount par value deficit Shares (deficiency)
----------------- ----------- ------------ ------------- --------------
Balance at January 1, 2000,
previously stated 5,327,473 $ 53,275 $129,397,259 $(128,812,179) $ 81,000) $ 557,355
Cumulative effect of restating inventory
reserves, and effect of correcting cost of
sales, see Note 4 (1,156,000) 309,000 81,000 (766,000)
----------------------------------------------------------------------------------------------
Balance at January 1, 2000, as restated 5,327,473 $ 53,275 $128,241,259 $(128,503,179) $ 0 $ (208,645)
Net proceeds from sale of common stock 11,635,451 116,354 6,980,595 7,096,949
Common stock issued as compensation 20,000 200 23,550 23,750
Common stock issued under Company 401(k) plan 78,914 789 79,409 80,198
Common stock issued as payment against
accounts payable 870,000 8,700 (8,700)
Employee stock option compensation 2,050 2,050
Compensation paid in cash in settlement of
obligation to issue common stock 282,506 282,506
Forgiveness of amount due GP Strategies 129,886 129,886
Settlement shares sold 382,515 382,515
Net loss, as restated (2,668,663) (2,668,663)
-----------------------------------------------------------------------------------------------
Balance at December 31, 2000 17,931,838 179,318 136,113,070 (131,171,842) 0 5,120,546
Common stock issued to Metacine 2,000,000 20,000 (20,000)
Common stock issued as compensation 50,000 500 12,780 13,280
Common stock issued under Company 401(k) plan 323,949 3,239 106,095 109,334
Proceeds from exercise of common stock options 2,244 23 538 561
Employee stock option compensation 5,553 5,553
Settlement shares sold 21,463 21,463
Net loss, as restated (6,434,958) (6,434,958)
-----------------------------------------------------------------------------------------------
Balance at December 31, 2001 20,308,031 203,080 136,239,499 (137,606,800) 0 (1,164,221)
Common stock issued under Company 401(k) plan 722,374 7,224 71,119 78,343
Fair value of warrants issued with
convertible notes and value of
beneficial conversion feature 500,000 500,000
Net loss (2,738,397) (2,738,397)
----------------------------------------------------------------------------------------------
Balance at December 31, 2002 21,030,405 $210,304 $136,810,618 $(140,345,197) $ 0 $(3,324,275)
The accompanying notes are an integral part of these consolidated financial statements.
INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31,
2002 2001 2000
-------- -------- --------
As Restated As Restated
(See Note 4) (See Note 4)
Cash flows from operating activities:
Net loss $(2,738,397) $(6,434,958) $(2,668,663)
Adjustments to reconcile net loss
to net cash used for operating activities:
Depreciation and amortization 425,077 507,507 502,157
Acquisition of in-process research and development 2,341,418
Equity in loss of Metacine 158,582
Gain on settlements of research-related
liabilities (456,998)
Provision for notes receivable 87,500 70,000
Non-cash compensation expense 78,343 128,167 388,504
Debt discount 281,863
Change in operating assets
and liabilities:
Accounts and other receivables 80,650 1,551,409 (1,639,237)
Inventories 81,424 (4,439) (105,474)
Prepaid expenses and other current assets 5,429 (120) 9,530
Accounts payable and accrued expenses 551,385 95,845 (1,497,126)
Amount due to GP Strategies 18,000 29,106 (87,112)
--------------- ------------ -------------
Net cash used for operating activities (1,216,226) (1,539,983) (5,484,419)
--------------- ------------ -------------
Cash flows from investing activities:
Additions to property, plant and equipment (46,994) (56,967)
Investments in Metacine and other assets (787,500) (170,000)
Reduction of other assets 10,000
--------------- ------------ ------------
Net cash provided by (used for)
investing activities 10,000 (834,494) (226,967)
--------------- ------------ -------------
Cash flows from financing activities:
Proceeds from convertible notes payable 500,000
Net proceeds from sale of common stock 7,096,949
Repayment of note payable to GP Strategies (100,000) (100,000)
Proceeds from exercise of common stock options 561
--------------- ------------ -------------
Net cash provided by (used for) financing
activities 400,000 (99,439) 7,096,949
--------------- ------------ -------------
Net increase (decrease) in cash and cash equivalents (806,226) (2,473,916) 1,385,563
Cash and cash equivalents at beginning of year 1,184,889 3,658,805 2,273,242
-------------- ------------ -------------
Cash and cash equivalents at end of year $ 378,663 $ 1,184,889 $ 3,658,805
============== ============ =============
The accompanying notes are an integral part of these consolidated financial
statements.
INTERFERON SCIENCES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1. Organization and Business
Interferon Sciences, Inc. (the "Company") is a biopharmaceutical
company that operates in a single segment and is engaged in the study,
manufacture, and sale of pharmaceutical products based on its highly purified,
multispecies, natural source alpha interferon ("Natural Alpha Interferon"). The
Company's ALFERON(R) N Injection (Interferon Alfa-n3) product has been approved
by the United States Food and Drug Administration ("FDA") for the treatment of
certain types of genital warts and the Company has studied its potential use in
the treatment of HIV, hepatitis C, and other indications. Alferon N Injection is
sold principally in the United States, however, a portion is sold in foreign
countries. For the years ended December 31, 2002, 2001 and 2000, domestic sales
totaled $1,926,466, $1,488,897, and $1,046,470, respectively, and foreign sales
totaled zero, $9,706, and $21,001, respectively. All identifiable assets are
located in the United States.
Subsequent to December 31, 2002, the Company sold its inventory and
granted a license to its products to Hemispherx Biopharma, Inc. See Note 20.
Integrated Commercialization Solutions, Inc. ("ICS"), a subsidiary of
AmerisourceBergen Corporation, is the sole United States distributor of ALFERON
N Injection. ICS distributes ALFERON N Injection to a limited number of
wholesalers throughout the United States.
Note 2. Summary of Significant Accounting Policies
Principles of consolidation -- The consolidated financial statements
include the operations of the Company and Interferon Sciences Development
Corporation ("ISD"), its wholly owned subsidiary. All significant intercompany
transactions and balances have been eliminated. The transactions and balances of
Metacine, Inc. are being accounted for under the equity method (see Note 7). The
losses of Metacine from April 9, 2001, the date of the Company's acquisition of
an 82% equity interest in Metacine through December 31, 2001, have been
reflected in the accompanying statement of operations as equity in loss of
Metacine to the extent of the Company's carrying value of the investment in
Metacine. At December 31, 2001, the carrying value was written down to $-0-.
Cash and cash equivalents -- The Company considers all highly liquid
instruments with maturities of three months or less from purchase date to be
cash equivalents.
Property, plant and equipment -- Property, plant and equipment are
carried at cost. Major additions and improvements are capitalized while
maintenance and repairs, which do not extend the lives of the assets, are
expensed.
Depreciation -- The Company provides for depreciation and amortization
of plant and equipment following the straight-line method over the estimated
useful lives of such assets as follows:
Class of Assets Estimated Useful Lives
Buildings and Improvements 15 to 30 years
Equipment 5 to 10 years
Depreciation expense for the years ended December 31, 2002, 2001 and
2000 was $396,922, $478,082 and $472,101, respectively.
Patent costs -- The Company capitalizes costs to obtain patents and
licenses. Patent costs are amortized over 17 years on a straight-line basis. To
the extent a patent is determined to be worthless, the related net capitalized
cost is immediately expensed.
Revenue recognition -- Title passes to the customer at the shipping
point and revenue is therefore recognized when the product is shipped. The
Company's product is also tested by its quality control department prior to
shipment. The Company has no other obligation associated with its products once
shipment has occurred.
Research and Development Costs - Research and development are expensed
when incurred. The types of costs included in research and development are:
salaries, supplies, clinical costs, facility costs and depreciation. All of
these expenditures were for Company sponsored research and development programs.
During 2000, the Company settled amounts owed by the Company on various research
related liabilities at a savings to the Company of approximately $457,000. The
amount was credited against research and development expenses in 2000.
Inventories -- Inventories, consisting of raw materials, work in
process and finished goods, are stated at the lower of cost or market on a FIFO
basis. Inventory in excess of the Company's estimated usage requirements is
written down to its estimated net realizable value. Inherent in the estimates of
net realizable value is management estimates related to the Company's future
manufacturing schedules, customer demand, possible alternative uses and ultimate
realization of potentially excess inventory.
Long-Lived Assets -- The Company reviews long-lived assets and certain
identifiable intangibles for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. Recoverability of assets to be held and used is measured by a
comparison of the carrying amount of an asset to future net cash flows expected
to be generated by the assets. If such assets are considered to be impaired, the
impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the estimated fair value of the assets. Assets to
be disposed of are reported at the lower of the carrying amount or estimated
fair value less costs to sell.
Stock option plan - The Company accounts for its stock-based
compensation to employees and members of the Board of Directors in accordance
with the provisions of Accounting Principles Board ("APB") Opinion No. 25,
"Accounting for Stock Issued to Employees," and related interpretations. As
such, compensation is recorded on the date of issuance or grant as the excess of
the current market value of the underlying stock over the purchase or exercise
price. Any deferred compensation is amortized over the respective vesting
periods of the equity instruments, if any. The Company has adopted the
disclosure provisions of Statement of Financial Accounting Standards No. 123
("SFAS No. 123"), "Accounting for Stock-Based Compensation," and Statement of
Financial Accounting Standards No. 148, "Accounting for Stock-Based Compensation
- - Transition and Disclosure," which was released in December 2002 as an
amendment of SFAS 123. The following table illustrates the effect on net loss
and loss per share if the fair value based method had been applied to all
awards.
Year Ended December 31,
2002 2001 2000
Reported net loss $(2,738,397) $(6,434,958) $(2,668,663)
Stock-based employee
compensation expense
included in reported net loss,
net of related tax effects -- -- --
Stock based employee
compensation determined under
the fair value based method,
net of related tax effects (94,165) (730,284) (481,151)
Pro forma net loss (2,832,562) (7,165,242) (3,149,814)
Loss per share
(basic and diluted)
As reported $ (.13) $ (.33) $ (.22)
Pro forma $ (.14) $ (.37) $ (.26)
During 2002 and 2001, the Company did not grant any stock options. The
per share weighted-average fair value of stock options granted during 2000 was
$.88 on the date of grant using the Black Scholes option-pricing model with the
following weighted-average assumptions: expected dividend yield of 0.0%,
risk-free interest rate of 6.1%, expected volatility of 142.4% and an expected
life of 3.0 years.
Loss per share -- Basic loss per share (EPS) are based upon the
weighted average number of common shares outstanding during the period. Diluted
EPS are based upon the weighted average number of common shares outstanding
during the period assuming the issuance of common shares for all dilutive
potential common shares outstanding. At December 31, 2002, 2001 and 2000, the
Company's options and warrants outstanding are anti-dilutive and therefore basic
and diluted EPS are the same.
Use of Estimates in the Preparation of Financial Statements - The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities, and disclosure of contingent assets and liabilities, at the date of
the financial statements, and the reported amounts of revenue and expenses
during the reporting period. Actual results could differ from those estimates.
Income taxes - Income taxes are accounted for under the asset and
liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their
respective tax bases and for operating loss and tax credit carryforwards.
Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in the results of
operations in the period that includes the enactment date. At December 31, 2002
and 2001, the Company has recorded a full valuation allowance for the net
deferred tax asset.
Recently Issued Accounting Standards
In June 2001, the FASB issued SFAS No. 141, Business Combinations, ("SFAS
No. 141") and SFAS No. 142, Goodwill and Other Intangible Assets ("SFAS No.
142"). SFAS No. 141 requires that the purchase method of accounting be used for
all business combinations. SFAS No. 141 specifies criteria that intangible
assets acquired in a business combination must meet to be recognized and
reported separately from goodwill. SFAS No. 142 requires that goodwill and
intangible assets with indefinite useful lives no longer be amortized, but
instead tested for impairment at least annually in accordance with the
provisions of SFAS No. 142. SFAS No. 142 also requires that intangible assets
with estimable useful lives be amortized over their respective estimated useful
lives to their estimated residual values, and reviewed for impairment in
accordance with SFAS No. 121 and subsequently, SFAS No. 144 after its adoption.
The Company adopted the provisions of SFAS No. 141 as of July 1, 2001, and
SFAS No. 142 as of January 1, 2002.
Upon adoption of SFAS No. 142, the Company was required to reassess the
useful lives and residual values of all intangible assets acquired, and make any
necessary amortization period adjustments by the end of the first interim period
after adoption. If an intangible asset was identified as having an indefinite
useful life, the Company would be required to test the intangible asset for
impairment in accordance with the provisions of SFAS No. 142 within the first
interim period. Impairment is measured as the excess of carrying value over the
fair value of an intangible asset with an indefinite life. Any impairment loss
would be measured as of the date of adoption and recognized as the cumulative
effect of a change in accounting principle in the first interim period.
As of the date of adoption of SFAS No. 142, the Company does not have any
goodwill and has unamortized identifiable intangible assets of approximately
$160,000, all of which is subject to the transition provisions of SFAS No. 142.
In August 2001, the FASB issued SFAS No. 144, Accounting for the
Impairment or Disposal of Long-Lived Assets ("SFAS No. 144"). SFAS No. 144
addresses financial accounting and reporting for the impairment or disposal of
long-lived assets. This Statement requires that long-lived assets be reviewed
for impairment whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. Recoverability of assets to
be held and used is measured by a comparison of the carrying amount of an asset
to future net cash flows expected to be generated by the asset. If the carrying
amount of an asset exceeds its estimated future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds
the fair value of the asset. SFAS No. 144 requires companies to separately
report discontinued operations and extends that reporting to a component of an
entity that either has been disposed of (by sale, abandonment, or in a
distribution to owners) or is classified as held for sale. Assets to be disposed
of are reported at the lower of the carrying amount or fair value less costs to
sell. The Company adopted SFAS No. 144 on January 1, 2002.
In April 2002, the FASB issued SFAS No. 145, "Rescission of FAS
Statements 4, 44 and 64, Amendment of FAS Statement 13 and Technical
Corrections." SFAS No. 145 eliminates Statement 4 (and Statement 64, as it
amends Statement 4), which required gains and losses from extinguishment of debt
to be aggregated and, if material, classified as an extraordinary item, and
thus, also the exception to applying Opinion 30 is eliminated as well. This
statement is effective for fiscal years beginning after May 2002 for the
provisions related to the rescission of Statements 4 and 64 and for all
transactions entered into beginning May 2002 for the provision related to the
amendment of Statement 13. The Company does not expect that the adoption of SFAS
No. 145 will have a material impact on its results of operations or financial
position.
In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs
associated with Exit or Disposal Activities." SFAS No. 146 requires recording
costs associated with exit or disposal activities at their fair values when a
liability has been incurred. Under previous guidance, certain exit costs were
accrued upon management's commitment to an exit plan. The Company is required to
adopt SFAS No. 146 on January 1, 2003. The Company does not expect the adoption
of SFAS No. 146 will have a material impact on its results of operations or
financial position.
In December 2002, the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation - Transition and Disclosure," an amendment to SFAS No.
123, "Accounting for Stock-Based Compensation." Provisions of this statement
provide two additional alternative transition methods: modified prospective
method and retroactive restatement method, for an entity that voluntary changes
to the fair value based method of accounting for stock-based employee
compensation. The statement eliminates the use of the original SFAS No. 123
prospective method of transition alternative for those entities that change to
the fair value based method in fiscal years beginning after December 15, 2003.
It also amends the disclosure provisions of SFAS No. 123 to require prominent
annual disclosure about the effects on reported net income in the Summary of
Significant Accounting Policies and also requires disclosure about these effects
in interim financial statements. These provisions are effective for financial
statements for fiscal years ending after December 15, 2002. Accordingly, the
Company adopted the applicable disclosure requirements of this statement for
year-end reporting. The transition provisions of this statement apply upon the
adoption of the SFAS No. 123 fair value based method. The Company did not change
its method of accounting for employee stock-based compensation from the
intrinsic method to the fair value based alternative.
Note 3. Operations
The Company has experienced significant operating losses since its
inception in 1980. As of December 31, 2002, the Company had an accumulated
deficit of approximately $140 million. For the years ended December 31, 2002,
2001 and 2000, the Company had losses from operations of approximately $2.9
million, $7.3 million, and $4.2 million, respectively. Also, the Company has
limited liquid resources. These factors raise substantial doubt about the
Company's ability to continue as a going concern. The consolidated financial
statements do not include any adjustments that might result from the outcome of
this uncertainty. Although the Company received FDA approval in 1989 to market
ALFERON N Injection in the United States for the treatment of certain genital
warts, the Company has had limited success in generating revenue from the sale
of ALFERON N Injection to date.
During the year ended December 31, 2002, the Company generated
$1,926,466 in revenue from the sale of ALFERON N Injection and received $528,276
from the sale of the Company's New Jersey net operating tax loss carryovers. In
addition, the Company completed a private placement of $500,000 of convertible
notes to accredited investors. At December 31, 2002, the Company had
approximately $379,000 of cash and cash equivalents, with which to support
future operating activities and to satisfy its financial obligations as they
become payable.
On March 11, 2003, the Company sold all its inventory related to its
ALFERON N Injection product and granted a three-year license to sell the product
to Hemispherx Biopharma, Inc. ("HEB"). In exchange for the inventory and
license, the Company received HEB common stock with a guaranteed value of
$675,000, an additional 62,500 shares of HEB common stock without a guaranteed
value, and a royalty equal to 6% of the net sales of ALFERON N Injection. The
HEB common stock will be subject to selling restrictions. In addition, HEB
assumed approximately $400,000 of the Company's payables and various other
commitments. The Company and HEB also entered into another agreement pursuant to
which the Company will sell to HEB, subject to regulatory approval, the
Company's real estate property, plant, equipment, furniture and fixtures, rights
to ALFERON N Injection and all of its patents, trademarks and other intellectual
property related to its natural alpha interferon business. In exchange, the
Company will receive $675,000 of HEB common stock with a guaranteed value, an
additional 62,500 shares of HEB common stock without a guaranteed value and a
royalty equal to 6% of the net sales of all products sold containing natural
alpha interferon. HEB will assume approximately $2.3 million of the Company's
indebtedness that currently encumbers its assets. In addition, HEB will fund the
operating costs of the Company's facility pending the completion of this
transaction. In the event the Company does not obtain regulatory approval prior
to September 12, 2003, either the Company or HEB may terminate the agreement and
not complete the transaction.
Based on the Company's sale to HEB, estimates of revenue, expenses, and
the timing of repayment of creditors, management believes that the Company has
sufficient resources to enable the Company to continue operations until the
third quarter of 2003. However, actual results, may differ materially from such
estimate, and no assurance can be given that additional funding will not be
required sooner than anticipated or that such additional funding, whether from
financial markets or from other sources, will be available when needed or on
terms acceptable to the Company. Insufficient funds will require the Company to
terminate operations.
Note 4. Restatement
At December 31, 1999, the balance of the inventory reserves has been
increased to eliminate the effect of the $766,000 reversal of inventory
previously written down. This retroactive adjustment results in increasing the
Accumulated Deficit at December 31, 1999 by $766,000 and decreasing inventory
and total assets by the same amount. In addition, a restatement was required to
correct cost of sales and equity in loss of Metacine. The Net Loss and loss per
share for the years ended December 31, 2000 and 2001 have also been similarly
revised as follows:
Year Ended December 31,
2000 2001
---- ----
Net Loss as previously reported $(2,981,672) $(7,249,576)
Effect of reversing inventory write (up) down(1) (71,300) 584,898
Effect of adjusting carrying value of inventory(2) 105,474 4,439
Elimination of adjustments for common stock
held by Red Cross(3) 278,835 (65,713)
Effect of correcting equity in loss of Metacine(4) -- 290,994
------------ ------------
Net Loss as restated $(2,668,663) $(6,434,958)
------------ ------------
Basic and diluted Net Loss per share
as previously stated $ (.25) $ (.37)
Effect of reversing inventory write down -- .03
Effect of adjusting carrying value of inventory .01 --
Elimination of adjustments for common stock
held by Red Cross .02 --
Effect of correcting equity in loss of Metacine -- .01
------------ ------------
Basic and diluted Net Loss per share as restated $ (.22) $ (.33)
============ ============
(1) To adjust for reversal of inventory write (up) down.
(2) To adjust the carrying value of inventory for production costs not capitalized.
(3) To adjust cost of sales for the change in market value of common stock held by American Red Cross.
(4) To adjust for the equity in the loss of Metacine in excess of the carrying basis.
Note 5. Agreements with Hoffmann-LaRoche
F. Hoffmann-La Roche Ltd. and Hoffmann-LaRoche, Inc. (collectively,
"Hoffmann") have been issued patents covering human alpha interferon in many
countries throughout the world. In 1995, the Company obtained a non-exclusive
perpetual license from Hoffmann (the "Hoffmann Agreement") that grants the
Company the worldwide rights to make, use, and sell, without a potential patent
infringement claim from Hoffmann, any formulation of Natural Alpha Interferon.
The Hoffmann Agreement permits the Company to grant marketing rights with
respect to Natural Alpha Interferon products to third parties, except that the
Company cannot grant marketing rights with respect to injectable products in any
country in which Hoffmann has patent rights covered by the Hoffmann Agreement
(the "Hoffmann Territory") to any third party not listed on a schedule of
approximately 50 potential marketing partners without the consent of Hoffmann,
which consent cannot be unreasonably withheld.
Under the terms of the Hoffmann Agreement, the Company is obligated to
pay Hoffmann an aggregate royalty on net sales (as defined) of Natural Alpha
Interferon products by the Company in an amount equal to (i) 8% of net sales in
the Hoffmann Territory, and 2% of net sales outside the Hoffmann Territory of
products manufactured in the Hoffmann Territory, up to $75,000,000 of net sales
in any calendar year and (ii) 9.5% of net sales in the Hoffmann Territory, and
2% of net sales outside the Hoffmann Territory of products manufactured in the
Hoffmann Territory, in excess of $75,000,000 of net sales in any calendar year,
provided that the total royalty payable in any calendar year shall not exceed
$8,000,000. For the years ended December 31, 2002, 2001 and 2000, the Company
recorded approximately $31,000, $60,000, and $42,000, in royalty expenses to
Hoffmann, respectively. The Hoffmann Agreement can be terminated by the Company
on 30 days notice with respect to the United States patent, any individual
foreign patent, or all patents owned by Hoffmann. If the Hoffmann Agreement is
terminated with respect to the patents owned by Hoffmann in a specified country,
such country is no longer included in the Hoffmann Territory. Accordingly, the
Company would not be permitted to market any formulation of alpha interferon in
such country.
Note 6. Research and Development Agreement with Interferon Sciences Research
Partners, Ltd.
In 1984, the Company organized ISD to act as the sole general partner
of Interferon Sciences Research Partners, Ltd., a New Jersey limited partnership
(the "Partnership"). The Company and the Partnership entered into a development
contract whereby the Company received substantially all of the net proceeds
($4,414,475) of the Partnership's public offering of limited partnership
interests. The Company used the proceeds to perform research, development and
clinical testing on behalf of the Partnership for the development of ALFERON Gel
containing recombinant interferon.
In connection with the formation of the Partnership, ISD agreed to make
additional cash contributions for purposes of continuing development of ALFERON
Gel if the Partnership exhausted its funds prior to development of such product.
ISD is wholly dependent upon the Company for capital to fund such commitment.
The Partnership exhausted its funds during 1986, and the Company contributed a
total of $1,997,000 during the period from 1986 to 1990, for the continued
development of ALFERON Gel. In 1987, the Company filed a Product License
Application with the FDA for approval to market ALFERON Gel. In February 1990,
the FDA indicated that additional process development and clinical trials would
be necessary prior to approval of ALFERON Gel. The Company believed, at that
time, that the costs to complete the required process development and clinical
trials would be substantial, and there could be no assurance that the clinical
trials would be successful.
As a result of the above events, in 1992, the Company withdrew its FDA
Product License Application for ALFERON Gel containing recombinant interferon.
In place of single species recombinant interferon, previously ALFERON Gel's
active ingredient, the Company commenced, in 1992, further development of
ALFERON Gel using the Company's natural source multi-species alpha interferon
("ALFERON N Gel"). However, at the present time, the Company is not actively
pursuing development of ALFERON N Gel and the Company does not have an
obligation to provide additional funding to the Partnership. Assuming successful
development and commercial exploitation of ALFERON N Gel, which to date has not
occurred, the Company may be obligated to pay the Partnership royalties equal to
4% of the Company's net sales of ALFERON N Gel and 15% of revenues received from
sublicensing ALFERON N Gel.
Note 7. Agreement with Metacine, Inc.
On July 28, 2000, the Company acquired for $100,000 an option to purchase
certain securities of Metacine, Inc. ("Metacine"), a company engaged in research
using dendritic cell technology, on the terms set forth below.
On April 9, 2001, the Company exercised its option to acquire an 82% equity
interest in Metacine. Pursuant to the agreement, as amended, the Company
received 700,000 shares of Metacine common stock and a five-year warrant to
purchase, at a price of $12.48 per share, 282,794 shares of Metacine common
stock in exchange for $300,000 in cash, an obligation to pay Metacine $
1,850,000 and $250,000 of services to be rendered by the Company by June 30,
2002. In addition, the Company issued Metacine 2,000,000 shares of the Company's
common stock. The agreement contains certain restrictions on the ability of
Metacine to sell the Company's shares and provides for the Company to make cash
payments ("Deficiency Payments") to Metacine to the extent Metacine has not
received from the sale of the Company's common stock, cumulative net proceeds of
$1,850,000 by September 30, 2002 or $400,000 of net proceeds per quarter
beginning with the period ending September 30, 2001 and $250,000 for the quarter
ending September 30, 2002. On October 4, 2001, the Company made a Deficiency
Payment to Metacine in the amount of $400,000 for the quarter ending September
30, 2001. The Company has not made the remainder of the Deficiency Payments in
the aggregate amount of $1,450,000. If Metacine sells all of the 2,000,000
shares received and the cumulative proceeds from the sales and any Deficiency
Payments are less than $1,850,000, the Company may issue to Metacine additional
shares of common stock at the Company's full discretion. These additional shares
would be treated in the same manner as the original 2,000,000 shares. In the
event that cumulative net proceeds to Metacine from the sale of the Company's
common stock exceed $1,850,000, any Deficiency Payments previously made by the
Company ($400,000 through December 31, 2002) would be repaid to the Company to
the extent these proceeds exceed $1,850,000. All additional proceeds beyond the
$1,850,000 and repayment of Deficiency Payments, if any, would be for the
benefit of Metacine. The Company was required to put in escrow 100,000 Metacine
shares to secure its obligations to render $250,000 of services to Metacine and
462,500 Metacine shares to secure its potential obligations to make Deficiency
Payments. Since the Company has not made $1,450,000 in Deficiency Payments and
has not rendered $250,000 of services to Metcine, Metacine could request 462,500
Metacine shares currently held in escrow to satisfy the Company's past due
obligations.
Although the Company is the majority owner of Metacine, the Company must,
on many matters, vote its shares of Metacine common stock in the same proportion
as votes cast by the minority stockholders of Metacine, except for certain
matters with respect for which the Company has protective rights. In accordance
with EITF Issue No. 96-16, Investor's Accounting for an Investee When the
Investor has a Majority of the Voting Interest but the Minority Shareholder or
Shareholders have Certain Approval or Veto Rights, the minority holders have
substantive participating rights which include controlling the selection,
termination and setting of compensation for Metacine management who are
responsible for implementing policies and procedures, making operating and
capital decisions (including establishing budgets) for Metacine and most other
ordinary operating matters, and therefore, the Company does not control
Metacine. In addition, the Company only has one representative on a board of
directors consisting of three directors. Accordingly, the acquisition is being
accounted for under the equity method.
Of the $2.5 million consideration paid for Metacine, $2,341,418 was
recorded as a charge for the acquisition of in-process research and development
("IPR&D") in 2001. The charge was recorded as the acquisition of IPR&D as
Metacine's primary asset is technology that has not reached technological
feasibility and has no alternative uses. The in-process research and development
expenses relate to a patent portfolio consisting of six issued patents, eight
pending patents and four invention disclosures related to the use of dendritic
cells for the treatment of various diseases. While the patent portfolio, when
viewed as a whole, represented a new approach to the treatment of various
diseases utilizing cell therapy, the six issued patents had no independent
commercial value. While the Company did not engage the services of an
independent appraiser to assess the fair value of the purchased in process
research and development, it considered the following factors: (i) any product
or process utilizing dendritic cells as a treatment for any disease would
regulated by the FDA and therefore would require extensive clinical testing
prior to the time any revenue would be generate from the sale of a product or
process, (ii) the cost of such clinical trials would be in excess of $
50,000,000, (iii) it would take between seven to ten years to complete such
clinical trials, (iv) there could be no assurance that even if Metacine could
obtain the funding required to complete the clinical trials (which was well
beyond Metacine's capability at the time Metacine acquired rights to the patent
portfolio), that the clinical trials would have shown the product or process
tested to be safe and effective. The Company's $1,850,000 obligation to
Metacine, less the $400,000 Deficiency Payment made in October 2001, has been
recorded as a current liability at December 31, 2002 and 2001. The $250,000 of
services to be provided has also been recorded as a current liability. Services
rendered to Metacine to date were immaterial and as such, the liability remained
unchanged at December 31, 2002 and 2001. The investment has been further reduced
to zero at December 31, 2001, by the Company's equity in the loss of Metacine of
$158,582 for the period from April 9, 2001 through December 31, 2001.
On April 1, 2003, the license granted by the University of Pittsburgh
to Metacine covering Metacine's technology was terminated due to non-payment by
Metacine.
Accordingly, the Company's has not reflected its share of its equity in
the losses in Metacine for the years ended December 31, 2002 and 2001 in the
amounts of $274,846 and $290,994, respectively.
The Company is currently in discussions with Metacine with respect to a
full settlement of the Company's obligations to Metacine.
Note 8. Inventories
Inventories, consisting of material, labor and overhead, are classified
as follows:
December 31,
2002 2001
-------------------------
As Restated
(See Note 4)
Finished goods $ 322,518 $ 1,263,696
Work in process 3,052,070 3,052,070
Raw materials 1,332,560 1,332,560
Less reserve for excess inventory (4,678,659) (5,538,413)
----------- ------------
$ 28,489 $ 109,913
=========== ============
Finished goods inventory consists of vials of ALFERON N Injection,
available for commercial and clinical use either immediately or upon final
release by quality assurance.
In light of the results of the Company's Phase 3 studies of ALFERON N
Injection in HIV and HCV-infected patients, the Company has recorded a reserve
against its inventory of ALFERON N Injection to reflect its estimated net
realizable value. The reserve was a result of the Company's assessment of
anticipated near-term projections of product to be sold or utilized in clinical
trials, giving consideration to historical sales levels. As a result,
inventories at December 31, 2002 and 2001, reflect a reserve for excess
inventory of $4,678,659 and $5,538,413, respectively.
Note 9. Convertible Notes Payable
In August 2002, the Company completed a private placement of $500,000
of convertible notes to accredited investors. Each note is convertible into the
Company's common stock at a price of $.05 per share (subject to adjustment to
70% of the market price of the Company's common stock under certain
circumstances) and bears interest at the rate of 10% per annum. $250,000 of the
convertible notes is due January 31, 2003 and the other $250,000 of the
convertible notes is due December 31, 2003. For each $100,000 principal amount
of notes issued, the investors received warrants to purchase an additional 10.2
million shares of the Company's common stock exercisable at $.01 per share. The
warrants were valued at $400,000 and are amortized as interest expense over the
terms of the respective notes. The transaction is subject to approval by the
shareholders of the Company. In the event that shareholder approval is not
obtained, the convertible noteholders could exercise their rights and call a
default making the convertible notes immediately due and payable. In addition,
these notes are convertible into common stock at a beneficial rate. The
beneficial conversion feature is valued at $100,000 and accounted for as debt
discount and is being amortized over the term of the notes.
Note 10. Income Taxes
As a result of the loss allocation rules contained in the Federal
income tax consolidated return regulations, approximately $5,900,000 of net
federal operating loss carryforwards, which expire from 2003 to 2006, are
available to the Company upon ceasing to be a member of GP Strategies's
consolidated return group in 1991. In addition, the Company has net federal
operating loss carryforwards for periods subsequent to May 31, 1991, and through
December 31, 2002 of approximately $104,000,000 that expire from 2006 to 2022.
In addition, the Company had state net operating loss carryforwards of
approximately $32,000,000 that expire from 2005 to 2009.
The Company believes that the events culminating with the closing of
its Common Stock Private Offering on November 6, 2000 may result in an
"ownership change" under Internal Revenue Code, Section 382, with respect to its
stock. The Company believes that as a result of the ownership change, the future
utility of its pre-change net operating losses may be significantly limited.
Further, the issuance of 51,000,000 warrants in August 2002 could also result in
an ownership change and further limit use of the net operating losses carried
forward.
The tax effects of temporary differences that give rise to deferred tax
assets and liabilities consist of the following as of December 31, 2002 and
2001:
Deferred tax assets 2002 2001
- ------------------- ---- -----
Net operating loss carryforwards $39,530,000 34,551,000
Tax credit carry-forwards -- 150,000
Inventory reserve 1,872,000 2,114,000
Property and equipment,
principally due to differences
in basis and depreciation 661,000 588,000
In-process technology costs -- 937,000
---------- -----------
Gross deferred tax asset 42,063,000 38,340,000
Valuation allowance (42,063,000) (38,340,000)
----------- -----------
Net deferred taxes $ --- $ ---
=========== ===========
A valuation allowance is provided when it is more likely than not that
some portion of the deferred tax asset will not be realized. The Company has
determined, based on the Company's history of annual net losses, that a full
valuation allowance is appropriate. The change in the valuation allowance for
2002 and 2001 was $3,723,000 and $2,411,000, respectively.
Based on the Company's net loss before income taxes in 2002, 2001 and
2000, the Company would have recorded a tax benefit. During each of these years,
the Company recorded increases in the valuation allowance due to uncertainty
regarding the realization of deferred taxes that reduced the Company's expected
income tax benefit to zero in these years.
The Company participates in the State of New Jersey's corporation
business tax benefit certificate transfer program (the "Program"), which allows
certain high technology and biotechnology companies to transfer unused New
Jersey net operating loss carryovers to other New Jersey corporation business
taxpayers. During 1999, the Company submitted an application to the New Jersey
Economic Development Authority (the "EDA") to participate in the Program and the
application was approved. The EDA then issued a certificate certifying the
Company's eligibility to participate in the Program and the amount of New Jersey
net operating loss carryovers the Company has available to transfer. Since New
Jersey law provides that net operating losses can be carried over for up to
seven years, the Company may be able to transfer its New Jersey net operating
losses from the last seven years. The Program requires that a purchaser pay at
least 75% of the amount of the surrendered tax benefit.
During 2002, 2001 and 2000, the Company completed the sale of
approximately $6.5 million, $12 million, and $19 million of its New Jersey tax
loss carryovers and received $0.53 million, $0.97 million, and $1.48 million,
which were recorded as a tax benefit from gains on sale of state net operating
loss carryovers on its Consolidated Statement of Operations in 2002, 2001 and
2000, respectively.
Note 11. Common Stock, Stock Options, Warrants and Other Shares Reserved
The Company has a stock option plan (the "Plan"), which authorizes a
committee of the Board of Directors to grant options, to purchase shares of
Common Stock, to officers, directors, employees and consultants of the Company.
Pursuant to the terms of the Plan, no option may be exercised after 10 years
from the date of grant. The Plan permits options to be granted at a price not
less than 85% of the fair market value, however, the options granted to date
have been at fair market value of the common stock at the date of the grant.
Employee stock option activity for options under the Plan during the
periods indicated is as follows:
Number of Weighted-Average
Shares Exercise Price
---------- ----------------
Balance at December 31, 1999 1,887,260 $ .25
Granted 61,710 1.10
Forfeited (2,580) .25
----------
Balance at December 31, 2000 1,946,390 .28
Exercised (2,244) .25
Forfeited (13,525) .35
----------
Balance at December 31, 2001 1,930,621 .28
Forfeited (22,546) .41
----------
Balance at December 31, 2002 1,908,075 .27
At December 31, 2002, the exercise prices and weighted-average remaining
contractual life of outstanding options were:
Number of
Options Life
------- ----
$ .25 - $1.00 1,854,475 1 year
$1.01 - $1.25 53,600 1 year
At December 31, 2002, the number of options exercisable was 1,908,075,
and the weighted-average exercise price of those options was $.27.
FASB Interpretation No. 44 provides guidance for applying APB Opinion
No. 25, "Accounting for Stock Issued to Employees" ("FIN 44"). It applies
prospectively to new awards, exchanges of awards in a business combination,
modifications to outstanding awards, and changes in grantee status on or after
July 1, 2000, except for provisions related to repricings and the definition of
an employee that apply to awards issued after December 15, 1998. The Company has
evaluated the financial impact of FIN 44 and has determined that the repricing
of employee stock options on October 27, 1999 falls within the guidance of FIN
44. On October 27, 1999, the Company repriced 429,475 stock options to $.25 per
share. On July 1, 2000, the implementation date of FIN 44, 352,823 shares of the
429,475 shares were fully vested (exercisable) and the closing price of the
Company's common stock on such date was $1.63 per share. Beginning on and after
July 1, 2000, the Company is required to record compensation expense on the
repriced vested options only when the market price exceeds $1.63 per share and
only on the amount in excess of $1.63 per share. For the repriced unvested stock
options, the intrinsic value measured at the July 1, 2000 effective date that is
attributable to the remaining vesting period will be recognized over that future
period. The unvested stock options at July 1, 2000 (76,652) were fully vested on
January 1, 2001. On December 31, 2002, the closing price of the Company's common
stock was $.05 per share and accordingly, under FIN 44, no compensation expense
was recorded on the repriced fully vested stock options of July 1, 2000 and on
the repriced unvested stock options of July 1, 2000.
Information regarding all Options and Warrants
Changes in options and warrants outstanding during the years ended
December 31, 2002, 2001 and 2000, and options and warrants exercisable and
shares reserved for issuance at December 31, 2002 are as follows:
The following table includes all options and warrants including
employee options (which are discussed above).
Price Range Number of
Per Share Shares
----------- ---------
Outstanding at December 31, 1999 $ .25 - $77.90 2,567,032
Granted .56 - 1.50 14,631,279
Terminated .25 - 77.90 (90,975)
--------------------- -----------
Outstanding at December 31, 2000 .25 - 48.00 17,107,336
Exercised .25 (2,244)
Terminated .25 - 48.00 (77,938)
--------------------- -----------
Outstanding at December 31, 2001 .25 - 36.00 17,027,154
Warrants Issued .01 - .01 51,000,000
Terminated .25 - 36.00 (49,510)
--------------------- ----------
Outstanding at December 31, 2002 .01 - 1.50 67,977,644
==========
Exercisable:
December 31, 2002 .25 - 1.50 16,977,644
==========
Shares reserved for issuance:
December 31, 2002 67,977,644
==========
Options and warrants outstanding and exercisable, and shares reserved
for issuance at December 31, 2002, include 500,000 shares under a warrant
agreement with GP Strategies. The warrants are priced at $1.00 per share and
expire on March 25, 2004.
Options and warrants outstanding and exercisable, and shares reserved
for issuance at December 31, 2002, include 11,635,451 shares under warrant
agreements with the purchasers of a 2000 private offering. The warrants are
priced at $1.50 per share and expire on April 17, 2005.
Options and warrants outstanding and exercisable, and shares reserved
for issuance at December 31, 2002, include 2,934,118 shares under a warrant
agreement to purchase 1,467,059 units. Each unit consists of a share of common
stock and a warrant to purchase an additional share of common stock at a price
of $1.50 per share, exercisable at a price of $.66 per unit. The units were
issued as compensation for services rendered to the Company in the 2000 private
offering and expire on April 17, 2005.
Options and warrants outstanding and shares reserved for issuance, at
December 31, 2002, include 51,000,000 shares under warrant agreements (subject
to shareholder approval) with the purchasers of the convertible notes. The
warrants are exercisable at $.01 per share upon shareholder approval and expire
in 2007.
Note 12. Savings Plan
The ISI Savings Plan (the "Savings Plan") permits pre-tax contributions
to the Savings Plan by participants pursuant to Section 401(k) of the Internal
Revenue Code of up to 15% of base compensation. The Company will match up to the
6% level of the participants' eligible contributions. The Savings Plan matches
40% in cash and 60% in the Company's common stock up to the 6% level. For 2002,
the Company's contribution to the Savings Plan, which was fully vested, was
$131,000, consisting of $52,657 in cash and $78,343 in stock. For 2001, the
Company's contribution to the Savings Plan was $176,000, consisting of $66,666
in cash and $109,334 in stock. For 2000, the Company's contribution to the
Savings Plan was $124,000, consisting of $43,802 in cash and $80,198 in stock.
Note 13. Common Stock Compensation and Profit Sharing Plan
Common Stock Compensation Plan
Effective October 1, 1997, the Company adopted the Common Stock
Compensation Plan (the "Stock Compensation Plan"), providing key employees with
the opportunity of receiving the Company's common stock as additional
compensation.
Pursuant to the terms of the Stock Compensation Plan, key employees
were to receive, as additional compensation, a pre-determined amount of the
Company's common stock in three equal installments on October 1, 1998, 1999 and
2000, provided that the key employees remain in the employ of the Company at
each such installment date. As of October 1, 2000, 1999 and 1998, a deferred
compensation liability of $289,920, $340,821 and $412,344, respectively, was
accrued for these employees based on the common stock market price of October 1,
1997. On October 1, 2000, 1999 and 1998, the Company paid the compensation in
cash in settlement of the Company's obligation to issue shares of common stock.
Accordingly, cash of $7,414, $2,131, and $25,947, respectively, was paid in
satisfaction of the accrued liability of $289,920, $340,821 and $412,344,
respectively. The difference of $282,506, $338,690, and $386,397 was credited to
additional paid in capital in 2000, 1999 and 1998, respectively.
Profit Sharing Plan
The Company has a Profit Sharing Plan (the "Profit Sharing Plan")
providing key employees and consultants with an opportunity to share in the
profits of the Company. The Profit Sharing Plan is administered by the Company's
Compensation Committee.
Pursuant to the terms of the Profit Sharing Plan, the Compensation
Committee, in its sole discretion, based upon the significance of the employee's
contributions to the operations of the Company, selects certain key employees
and consultants of the Company who are entitled to participate in the Profit
Sharing Plan and determines the extent of their participation. The amount of the
Company's profits available for distribution to the participants (the
"Distribution Pool") is the lesser of (a) 10% of the Company's income before
taxes and profit sharing expense and (b) an amount equal to 100% of the base
salary for such year of all the participants in the Profit Sharing Plan.
The Compensation Committee may require as a condition to participation
that a participant remain in the employ of the Company until the end of the
fiscal year for which payment is to be made. Payments required to be made under
the Profit Sharing Plan must be made within 10 days of the filing of the
Company's tax return. To date, there have been no contributions by the Company
under the Profit Sharing Plan.
Note 14. Related Party Transactions
GP Strategies owns less than 5% of the Company's common stock as of
December 31, 2002. The Company was a party to a management agreement with GP
Strategies, pursuant to which certain legal, financial and administrative
services had been provided by employees of GP Strategies. The management
agreement was terminated on March 27, 2000 (See Note 16).
See Note 16 for information with respect to royalty obligations to GP
Strategies.
Note 15. Supplemental Statement of Cash Flow Information
The Company paid no income taxes or interest during the three-year
period ended December 31, 2002.
During the years ended December 31, 2002, 2001 and 2000 the following
non-cash financing and investing activities occurred:
2002:
None
2001:
The Company issued 2,000,000 shares, with a guaranteed value of
$1,850,000, of common stock and committed to provide $250,000 of services to be
rendered by the Company to Metacine (see Note 7).
The Company reduced capital in excess of par value and the
corresponding liability by $21,463 for settlement shares sold.
2000:
The Company issued 870,000 shares of common stock as payment related to
accounts payable (see Note 16). The Company credited capital in excess
of par value for forgiveness of $129,886 of debt due GP Strategies.
The Company reduced capital in excess of par value and the
corresponding liability by $382,515 for settlement shares sold.
Note 16. Commitments
The Company obtained human white blood cells used in the manufacture of
ALFERON N Injection from several sources, including the Red Cross pursuant to a
supply agreement dated April 1, 1997 (the "Supply Agreement"). The Company will
not need to purchase more human white blood cells until such time as production
of crude alpha interferon is resumed. Under the terms of the Supply Agreement,
the Company was obligated to purchase a minimum amount of human white blood
cells each month through March 1999 (the "Minimum Purchase Commitment"), with an
aggregate Minimum Purchase Commitment during the period from April 1998 through
March 1999 in excess of $3,000,000. As of November 23, 1998, the Company owed
the Red Cross approximately $1.46 million plus interest at the rate of 6% per
annum accruing from April 1, 1998 (the "Red Cross Liability") for white blood
cells purchased pursuant to the Supply Agreement.
Pursuant to an agreement dated November 23, 1998, the Company granted
the Red Cross a security interest in certain assets to secure the Red Cross
Liability, issued to the Red Cross 300,000 shares of common stock and agreed to
issue additional shares at some future date as requested by the Red Cross to
satisfy any remaining amount of the Red Cross Liability. The Red Cross agreed
that any net proceeds received by it upon sale of such shares would be applied
against the Red Cross Liability and that at such time as the Red Cross Liability
was paid in full, the Minimum Purchase Commitment would be deleted effective
April 1,1998 and any then existing breaches of the Minimum Purchase Commitment
would be waived. In January 1999 the Company granted the Red Cross a security
interest (the "Security Interest") in, among other things, the Company's real
estate, equipment inventory, receivables, and New Jersey net operating loss
carryovers to secure repayment of the Red Cross Liability, and the Red Cross
agreed to forbear from exercising its rights under the Supply Agreement,
including with respect to collecting the Red Cross Liability until June 30, 1999
(which was subsequently extended until December 31, 1999). On December 29, 1999,
the Company, the Red Cross and GP Strategies entered in an agreement pursuant to
which the Red Cross agreed that until September 30, 2000 it would forbear from
exercising its rights under (i) the Supply Agreement, including with respect to
collecting the Red Cross Liability, and (ii) the Security Interest. In
connection with the Asset Sale Transactions, the Company, HEB and the Red Cross
entered into a similar agreement pursuant to which the Red Cross agreed to
forbear from exercising its rights until May 31, 2003 and the Red Cross agreed
to accept HEB common stock with a guaranteed value of $500,000 in full
settlement of all of the Company's obligations to the Red Cross. Under the terms
of such agreement, if HEB does not make such payment, the Red Cross has the
right to sell the Company's real estate.
During 1999, the Red Cross sold 27,000 of the Settlement Shares and
sold the balance of such shares (273,000 shares) during the first quarter of
2000. As a result, the net proceeds from the sales of the Settlement Shares,
$33,000 in 1999 and $368,000 in 2000, were applied against the liability to the
Red Cross. The remaining liability to the Red Cross included in accounts payable
on the consolidated balance sheet at December 31, 2002 and 2001 was
approximately $1,403,000 and $1,339,000, respectively. On October 30, 2000, the
Company issued an additional 800,000 shares to the Red Cross. The net proceeds
from the sale of such shares by the Red Cross will be applied against the
remaining liability of $1,403,000 owed to the Red Cross. However, there can be
no assurance that the net proceeds from the sale of such shares will be
sufficient to extinguish the remaining liability owed the Red Cross.
Pursuant to an agreement dated March 25, 1999, GP Strategies loaned the
Company $500,000. In return, the Company granted GP Strategies (i) a first
mortgage on the Company's real estate, (ii) a two-year option (which has
expired) to purchase the Company's real estate, provided that the Company has
terminated its operations and the Red Cross Liability has been repaid, and (iii)
a two-year right of first refusal (which has expired) in the event the Company
desires to sell its real estate. In addition, the Company issued GP Strategies
500,000 shares of Common Stock and a five-year warrant to purchase 500,000
shares of Common Stock at a price of $1 per share. The common stock and warrants
issued to GP Strategies were valued at $500,000 and recorded as a financing cost
and amortized over the original period of the GP Strategies Debt in 1999.
Pursuant to the agreement, the Company has issued a note to GP Strategies
representing the GP Strategies Debt, which note was originally due on September
30, 1999 (but extended to June 30, 2001) and bears interest, payable at
maturity, at the rate of 6% per annum. In addition, at that time the Company
negotiated a subordination agreement with the Red Cross pursuant to which the
Red Cross agreed that its lien on the Company's real estate is subordinate to GP
Strategies' lien. On March 27, 2000, the Company and GP Strategies entered into
an agreement pursuant to which (i) the GP Strategies Debt was extended until
June 30, 2001 and (ii) the Management Agreement between the Company and GP
Strategies was terminated and all intercompany accounts between the Company and
GP Strategies (other than the GP Strategies Debt) in the amount of approximately
$130,000 were discharged which was recorded as a credit to capital in excess of
par value. On August 23, 2001, the Company and GP Strategies entered into an
agreement pursuant to which the GP Strategies Debt was extended to March 15,
2002. During 2001, the Company paid GP Strategies $100,000 to reduce the GP
Strategies Debt. In addition, in January 2002, the Company paid GP Strategies
$100,000 to further reduce the GP Strategies Debt. Interest expense accrued to
GP Strategies was $18,000, $27,937 and $22,500 for the years ended December
31,2002, 2001 and 2000, respectively. In connection with the Asset Sale
Transactions, the Company, HEB and GP Strategies entered into a similar
agreement pursuant to which GP Strategies agreed to forbear from exercising its
rights until May 31, 2003 and GP Strategies agreed to accept HEB common stock
with a guaranteed value of $425,000 in full settlement of all the Company's
obligations to GP Strategies. Under the terms of such agreement, if HEB does not
make such payment, GP Strategies has the right to sell the Company's real
estate.
As consideration for the transfer to the Company of certain licenses,
rights and assets upon the formation of the Company by GP Strategies, the
Company agreed to pay GP Strategies royalties of $1,000,000, but such payments
will be made only with respect to those years in which the Company has income
before income taxes, and will be limited to 25% of such income. Through December
31, 2002, the Company has not generated income before taxes and therefore has
not accrued or paid royalties to GP Strategies.
See Notes 5 and 6 for information relating to royalties payable to
Hoffmann and the Partnership, respectively.
Note 17. Quarterly Financial Data (unaudited)
The following summarizes the Company's unaudited quarterly results for 2002 and
2001.
2002 Quarters First Second Third Fourth
------ ------ ----- ------
As Restated(2) As Restated(2) As Restated(2)
Thousands of dollars except per share data
Revenues $ 784 $ 176 $ 687 $ 279
Gross profit (loss)(1) 369 (149) 254 (30)
Net loss (693) (949) (639) (457)
Basic and diluted net loss per share (.03) (.05) (.03) (.02)
2001 Quarters First Second Third Fourth
------ ------ ----- ------
As Restated(2) As Restated(2) As Restated(2) As Restated(2)
Thousands of dollars except per share data
Revenues $ 371 $ 344 $ 459 $ 325
Gross profit (loss)(1) (44) 22 98 (63)
Net loss (1,272) (3,659) (1,060) (444)
Basic and diluted net loss per share (.07) (.18) (.05) (.02)
(1) Gross profit (loss) is calculated as revenue less cost of goods sold and
excess/idle production costs.
(2) Restatement
2002 Quarters First Second Third
Gross profit (loss) as previously reported $ (35) $ (245) $ 263
Effect of reversing inventory
write(up) down(a) 252 -- --
Effect of adjusting carrying value of
inventory(b) (32) (8) (49)
Elimination of adjustments for common
stock held by Red Cross(c) 184 104 40
----------------------------------------------
Gross profit (loss) as restated $ 369 $ (149) $ 254
----------------------------------------------
Net loss as previously stated $ (1,289) $ (1,429) $ (655)
Net effect of gross profit adjustments
from above 404 96 (9)
Effect of correcting equity in loss of
Metacine(d) 112 124 39
Elimination of adjustments for common
stock held by Metacine(e) 80 260 100
Amortization of Debt Discount(f) -- -- (114)
-----------------------------------------------
Net loss as restated $ (693) $ (949) $ (639)
-----------------------------------------------
Basic and diluted net loss per share
as previously stated $ (0.06) $ (0.07) $ (0.03)
Effect of gross profit adjustments 0.02 -- --
Effect of Metacine related adjustments 0.01 0.02 0.01
Effect of amortization of debt discount -- -- (0.01)
-----------------------------------------------
Basic and diluted net loss per share
as restated $ (0.03) $ (0.05) $ (0.03)
-----------------------------------------------
(a) To adjust for reversal of inventory write (up) down.
(b) To adjust the carrying value of inventory for production costs not capitalized.
(c) To adjust cost of sales for the change in market value of common stock held by the American
Red Cross.
(d) To adjust for the equity in the loss of Metacine in excess of the carrying basis.
(e) To adjust other expenses for the change in market value of common stock held by Metacine.
(f) To amortize debt discount on convertible notes issued during the year.
2001 Quarters First Second Third Fourth
Gross profit (loss) as previously
reported $ (270) $ (56) $ (267) $ 81
Effect of reversing inventory
write(up) down(a) 159 116 192 118
Effect of adjusting carrying value of
inventory(b) (15) 53 (19) (14)
Elimination of adjustments for common
stock held by Red Cross(c) 82 (91) 192 (248)
--------------------------------------------------
Gross profit (loss) as restated $ (44) $ 22 $ 98 $ (63)
--------------------------------------------------
Net loss as previously stated $(1,498) $(3,737) $(1,665) $ (350)
Net effect of gross profit adjustments
from above 226 78 365 (144)
Effect of correcting equity in loss of
Metacine(d) -- -- -- 290
Elimination of adjustments for common
stock held by Metacine(e) -- -- 240 (240)
--------------------------------------------------
Net loss as restated $(1,272) $(3,659) $(1,060) $ (444)
--------------------------------------------------
Basic and diluted net loss per share
as previously stated $ (0.08) $ (0.19) $(0.08) $(0.02)
Effect of gross profit adjustments 0.01 -- 0.02 --
Effect of Metacine related adjustments -- -- 0.01 --
--------------------------------------------------
Basic and diluted net loss per share
as restated $ (0.07) $ (0.19) $(0.05) $(0.02)
--------------------------------------------------
(a) To adjust for reversal of inventory write (up) down.
(b) To adjust the carrying value of inventory for production costs not capitalized.
(c) To adjust cost of sales for the change in market value of common stock held by the American
Red Cross.
(d) To adjust for the equity in the loss of Metacine in excess of the carrying basis.
(e) To adjust other expenses for the change in market value of common stock held by Metacine.
Note 18. Fair Value of Financial Instruments
The carrying values of financial instruments, assuming the Company
continues as a going concern, including cash and cash equivalents, accounts
receivable, accounts payable, accrued expenses and note payable approximate fair
values, because of the short term nature or interest rates that approximate
current rates.
Note 19. Agreement with Mayo
In April 2001, the Company entered into a technology license agreement
with Mayo Foundation for Medical Education and Research ("Mayo") under which the
Company obtained certain technology rights. The Company has committed to fund
approximately $400,000 of costs related to a clinical trial beginning in
December 2001 and which is currently expected to take at least two years from
the date hereof to complete. The Company paid Mayo $100,000 related to this
clinical trial in 2001, incurred $101,565 in 2002 and will owe other amounts
upon the completion of certain parts of the trial, with the last payment due
upon receipt of the final written report on the trial. The Company can terminate
this agreement up to 60 days after receipt of this report. After expiration of
this ability to terminate, the Company must issue 25,000 shares of the Company's
common stock to Mayo and must pay milestone payments upon certain regulatory or
other events and royalties on future sales, if any. In addition, the Company
paid $60,000 to Mayo related to the agreement in 2001. Under the terms of the
Asset Sales Transactions, the Company's right to continue this agreement and the
obligation owed to Mayo was transferred to HEB. The Company did not generate any
revenues from this agreement for each of the three years ended December 31,
2002.
Note 20. Subsequent Event
On March 11, 2003, the Company sold all its inventory related to its
ALFERON N Injection product and granted a license to sell the product to
Hemispherx Biopharma, Inc. ("HEB"). In exchange for the inventory and license,
the Company received HEB common stock with a guaranteed value of $675,000, an
additional 62,500 shares of HEB common stock without a guaranteed value, and a
royalty equal to 6% of the net sales of ALFERON N Injection. The HEB common
stock will be subject to selling restrictions. In addition, HEB assumed
approximately $400,000 of the Company's payables and various other commitments.
The Company and HEB also entered into another agreement pursuant to which the
Company will sell to HEB, subject to regulatory approval, the Company's real
estate property, plant, equipment, furniture and fixtures, rights to ALFERON N
Injection and all of its patents, trademarks and other intellectual property
related to its natural alpha interferon business. In exchange, the Company will
receive $675,000 of HEB common stock with a guaranteed value, an additional
62,500 shares of HEB common stock without a guaranteed value and a royalty equal
to 6% of the net sales of all products sold containing natural alpha interferon.
HEB will assume approximately $1.5 million of the Company's indebtedness that
currently encumbers its assets. In addition, HEB will fund the operating costs
of the Company's facility pending the completion of this transaction. In the
event the Company does not obtain regulatory approval prior to September 12,
2003, either the Company or HEB may terminate the agreement and not complete the
transaction.
In March 2003, the Company sold 15,000,000 shares of its common stock
in a private placement transaction to an investor for $150,000. In connection
with this private placement, the Company also sold, for $1,000, 15,000,000
warrants exercisable at $.01 per share and expiring in March 2008.
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
On November 6, 2002, the Company reported on Form 8-K that KPMG, LLP
resigned its engagement as the Company's independent accountant.
PART III
Item 10. Directors and Executive Officers of the Registrant
Set forth below are the officers and directors of the Company as of
August 1, 2003.
Samuel H. Ronel, Ph.D. has been Chairman of the Board since February
1997 and was Vice Chairman of the Board from January 1996 to February 1997 and
President, Chief Executive Officer, and a director of the Company from 1981 to
January 1996. He was responsible for the interferon research and development
program since its inception in 1979. Dr. Ronel joined GP Strategies in 1970 and
served as the Vice President of Research and Development of GP Strategies and as
the President of Hydro Med Sciences, a division of GP Strategies, from 1976 to
September 1996. Dr. Ronel served as President of the Association of
Biotechnology Companies, an international organization representing United
States and foreign biotechnology firms, from 1986-88 and has served as a member
of its Board of Directors until 1993. Dr. Ronel was elected to the Board of
Directors of the Biotechnology Industry Organization from 1993 to 1995 and to
the Governing Body of the Emerging Companies Section from 1993 to 1997. Since
1999 he has been a member of the Technology Advisory Board of the New Jersey
Economic Development Authority. Age 67.
Lawrence M. Gordon has been Chief Executive Officer and a director of
the Company since January 1996, Vice President of the Company from June 1991 to
January 1996, General Counsel of the Company from 1984 to January 1996. Age 49.
Stanley G. Schutzbank, Ph.D. has been President of the Company since
January 1996, Executive Vice President of the Company from 1981 to January 1996,
and a director of the Company since 1981 and has been associated with the
interferon research and development program since its inception in 1979. He is
involved with all facets of administration and planning of the Company and has
coordinated compliance with FDA regulations governing manufacturing and clinical
testing of interferon, leading to the approval of ALFERON N Injection in 1989.
Dr. Schutzbank joined GP Strategies in 1972 and served as the Corporate Director
of Regulatory and Clinical Affairs of GP Strategies from 1976 to September 1996
and as Executive Vice President of Hydro Med Sciences from 1982 to September
1996. Dr. Schutzbank is a member of the Regulatory Affairs Professionals Society
(RAPS) and has served as Chairman of the Regulatory Affairs Certification Board
from its inception until 1994. Dr. Schutzbank received the 1991 Richard E. Greco
Regulatory Affairs Professional of the Year Award for his leadership in
developing the United States Regulatory Affairs Certification Program. In
September 1995, Dr. Schutzbank was elected to serve as President-elect in 1996,
President in 1997, and Chairman of the Board in 1998 of RAPS. In October 2000,
Dr. Schutzbank received the Leonard J. Stauffer Award from RAPS. RAPS gives this
award once each year to a Regulatory Affairs Certified (RAC) individual who
exemplifies outstanding service to the RAC Program and/or mentoring in the
regulatory affairs profession. Age 57.
Donald W. Anderson has been the Controller of the Company since 1981
and Corporate Secretary of the Company since 1988. He was an officer of various
subsidiaries of GP Strategies from 1976 to September 1996. Age 53.
Sheldon L. Glashow, Ph.D. has been a director of the Company since 1991. He
has been a director of GSE Systems, Inc. since 1995, and a director of CalCol,
Inc. since 1994. Dr. Glashow is the Higgins Professor of Physics and the Mellon
Professor of the Sciences at Harvard University. He was a Distinguished
Professor and visiting Professor of Physics at Boston University. In 1971, he
received the Nobel Prize in Physics. Age 69.
Item 11. Executive Compensation
The following table presents the compensation paid by the Company to
its five most highly compensated executive officers for the years ended December
31, 2002, 2001 and 2000.
SUMMARY COMPENSATION TABLE
Long-Term
Annual Compensation Compensation Awards
------------------- -----------------------------
Stock All Other
Year Salary Bonus Options Compensation
Name and Principal Position ($) ($) (#) ($) (2)
- --------------------------- ---- ------ ------ -------- ------------
Lawrence M. Gordon 2002 191,735(1) - 0 - - 0 - 11,810
Chief Executive Officer 2001 321,619 - 0 - - 0 - 12,182
2000 328,790 - 0 - - 0 - 12,275
Samuel H. Ronel, Ph.D. 2002 109,573(1) - 0 - - 0 - 12,640
Chairman of the Board 2001 179,400 - 0 - - 0 - 17,125
2000 190,250 - 0 - - 0 - 13,733
Stanley G. Schutzbank, Ph.D. 2002 157,981(1) - 0 - - 0 - 11,543
President 2001 257,500 - 0 - - 0 - 13,435
2000 248,112 - 0 - - 0 - 13,375
- ------------
(1) In 2002, due to the financial condition of the Company, Messrs. Gordon,
Ronel and Schutzbank reduced the amount of time they spent on Company
business.
(2) Matching contribution by the Company to the 401(k) Savings Plan, payments
by the Company for Group Term Life, and payments made by the Company under
the Common Stock Compensation Plan. The Common Stock Compensation Plan
ended on October 1, 2000.
The following table sets forth information for the named executive
officers regarding the unexercised options held at December 31, 2002. No options
were exercised by the named executive officers during the year ended December
31, 2002.
AGGREGATED DECEMBER 31, 2002 OPTION VALUES
Number of Unexercised Value of Unexercised
Options at In-the-Money Options at
December 31, 2002(#) December 31, 2002($)(1)
Exercisable/Unexercisable Exercisable/Unexercisable
------------------------- -------------------------
Lawrence M. Gordon 509,005 - 0 - - 0 - N/A
Samuel H. Ronel, Ph.D. 312,265 - 0 - - 0 - N/A
Stanley G. Schutzbank, Ph.D. 484,875 - 0 - - 0 - N/A
- -------------------
(1) Calculated based on the closing price of the Common Stock as reported on the OTC Bulletin Board on December 31, 2002.
Item 12. Security Ownership Of Directors And Named Executive Officers
Principal Stockholders
The following table sets forth the number of shares of Common Stock
beneficially owned as of August 1, 2003, by each person who is known by the
Company to own beneficially more than 5% of the Company's outstanding Common
Stock.
Name and Address Number of Shares Percent of
of Beneficial Owner Beneficially Owned Class
- ------------------- ------------------ ----------
Margie Chassman 16,000,032 (1) 44.1 %
445 West 23rd Street
New York, New York 10011
(1) Does not include (i) 1,666,667 shares that may be acquired upon the exercise
of warrants, exercisable, commencing March 2004, until April 2005, at a price of
$1.50 per share, and (ii) 15,000,000 shares that may be acquired upon the
exercise of warrants, exercisable, commencing March 2004, until March 2008, at a
price of $ .01 per share.
The following table sets forth, as of March 31, 2003, beneficial
ownership of shares of Common Stock of the Company by each director, each of the
named executive officers and all directors and executive officers as a group.
Of Total Number
of Shares
Beneficially
Total Number Percent of Owned
of Shares Common Shares which
Beneficially Stock May be Acquired
Name Owned Owned(1) Within 60 Days
- ---- ------------ ---------- ---------------
Samuel H. Ronel, Ph.D. 396,567 1.3% 312,265
Lawrence M. Gordon 626,167 2.1% 509,005
Stanley G. Schutzbank, Ph.D. 589,984 1.9% 584,875
Sheldon L. Glashow 12,250 * 12,250
Directors and Executive
Officers as a Group
(4 persons) 1,624,968 6.3% 1,318,395
-------------
* The number of shares owned is less than one percent of the outstanding shares
of Common Stock.
(1) The percentage of class calculation assumes for each beneficial owner that
all of the options or warrants are exercised in full only by the named
beneficial owner and that no other options or warrants are deemed to be
exercised by any other stockholders.
Item 13. Certain Relationships and Related Transactions.
Employment Agreements
As of October 1, 1997, Lawrence M. Gordon entered into an employment
agreement with the Company pursuant to which Mr. Gordon is employed as the Chief
Executive Officer of the Company until December 31, 2001. On December 31, 1999,
and on each December 31 of each year thereafter, the employment period is
automatically extended for one additional year unless, not later than June 30
immediately preceding any such December 31, either party delivers to the other
written notice that the employment period is not further extended.
Commencing January 1, 1997, Mr. Gordon's base annual salary is
$250,000, subject to annual increases of 6%. The Company's Board of Directors
may determine Mr. Gordon's bonus for each year, and whether to grant Mr. Gordon
additional options, based upon the Company's revenues, profits or losses,
financing activities, progress in clinical trials, and such other factors deemed
relevant by the Board.
As of July 1, 2000, Stanley G. Schutzbank and Samuel H. Ronel entered
into employment agreements with the Company pursuant to which Dr. Schutzbank is
employed as President of the Company and Dr. Ronel is employed as Chairman of
the Board of the Company until December 31, 2003. On December 31, 2001 for Dr.
Schutzbank and December 31, 2002 for Dr. Ronel, and on each December 31 of each
year thereafter, the employment period is automatically extended for one
additional year unless, not later than June 30 immediately preceding any such
December 31, either party delivers to the other written notice that the
employment period is not further extended.
Dr. Schutzbank's base annual salary is $250,000, subject to annual
increases of 6%, and Dr. Ronel's base annual salary is $175,000, subject to such
increases as may be granted by the Board. The Board may determine Dr.
Schutzbank's and Dr. Ronel's bonus for each year, and whether to grant them
stock options, based upon the Company's revenues, profits or losses, financing
activities, progress in clinical trials, and such other factors deemed relevant
by the Board.
The Company may terminate each of the employment agreements for Cause,
which is defined as (i) the willful and continued failure by the employee to
substantially perform his duties or obligations or (ii) the willful engaging by
the employee in misconduct which is materially monetarily injurious to the
Company. If an employment agreement is terminated for Cause, the Company is
required to pay the employee his full salary through the termination date.
Each of the employees can terminate his employment agreement for Good
Reason, which is defined as (i) a change in control of the Company or (ii) a
failure by the Company to comply with any material provision of the employment
agreement which has not been cured within ten days after notice. A "change in
control" of the Company is defined as (i) a change in control of a nature that
would be required to be reported in response to Item 1(a) of Current Report on
Form 8-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
(the "Exchange Act"), (ii) any "person" (as such term is used in Sections 13(d)
and 14(d) of the Exchange Act) is or becomes the "beneficial owner" (as defined
in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of
the Company representing 20% or more of the combined voting power of the
Company's then outstanding securities, or (iii) at any time individuals who were
either nominated for election or elected by the Board of Directors of the
Company cease for any reason to constitute at least a majority of the Board.
If the Company wrongfully terminates an employment agreement or the
employee terminates his employment agreement for Good Reason, then (i) the
Company is required to pay the employee his full salary through the termination
date; (ii) the Company is required to pay as severance pay to the employee an
amount equal to (a) his average annual cash compensation received from the
Company during the three full calendar years immediately preceding the
termination date (or, if the termination date is prior to December 31, 2002,
during the full calendar years commencing with calendar year 2000 preceding the
termination date), multiplied by (b) the greater of (I) the number of years
(including partial years) that would have been remaining in the employment
period if the employment agreement had not so terminated and (II) three (one and
one-half in the case of Dr. Ronel), such payment to be made (c) if termination
is based on a change of control of the Company, in a lump sum on or before the
fifth day following the termination date or (d) if termination results from any
other cause, in substantially equal semimonthly installments payable over the
number of years (including partial years) that would have been remaining in the
employment period if the employment agreement had not so terminated; (iii) all
options to purchase the Company's common stock granted to the employee under the
Company's option plan or otherwise immediately become fully vested and terminate
on such date as they would have terminated if the employee's employment by the
Company had not terminated and, if the employee's termination is based on a
change of control of the Company and the employee elects to surrender any or all
of such options to the Company, the Company is required to pay the employee a
lump sum cash payment equal to the excess of (a) the fair market value on the
termination date of the securities issuable upon exercise of the options
surrendered over (b) the aggregate exercise price of the options surrendered;
and (iv) if termination of the employment agreement arises out of a breach by
the Company, the Company is required to pay all other damages to which the
employee may be entitled as a result of such breach. If the employment agreement
is terminated for any reason other than Cause, the Company is required to
maintain in full force and effect, for a number of years equal to the greater of
(i) the number of years (including partial years) that would have been remaining
in the employment period if the employment agreement had not so terminated and
(ii) three (one and one-half in the case of Dr. Ronel), all employee benefit
plans and programs in which the employee was entitled to participate immediately
prior to the termination date.
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K
(a)(1) The following financial statements are included in Part II, Item 8:
Page
Independent Auditors' Report 21
Financial Statements:
Consolidated Balance Sheets - December 31, 2002 and 2001 22
Consolidated Statements of Operations - Years ended
December 31, 2002, 2001 and 2000 23
Consolidated Statements of Changes in Stockholders' Equity
Capital Deficiency - Years ended December 31, 2002, 2001 and 2000 24
Consolidated Statements of Cash Flows - Years ended
December 31, 2002, 2001 and 2000 25
Notes to Consolidated Financial Statements 26
(a)(2) The following is a list of all financial schedules for 2002,
filed as part of this report:
Schedule II - Valuation and Qualifying Accounts 51
Schedules other than that listed above have been omitted because
they are not required or are not applicable or the required
information has been included in the financial statements or the
notes thereto.
(a)(3) See accompanying Index to Exhibits
(b) The Registrant filed Form 8-K Current Report dated November 6,
2002 reporting that KPMG, LLP resigned its engagement as the
Registrant's independent accountant.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
INTERFERON SCIENCES, INC.
By: /s/ Lawrence M. Gordon
-----------------------
Lawrence M. Gordon
Chief Executive Officer
Dated: August 5, 2003
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Signature Title Date
/s/ Samuel H. Ronel Chairman of the Board August 5, 2003
- -------------------------
Samuel H. Ronel, Ph.D.
/s/ Lawrence M. Gordon Chief Executive Officer and Director
- ------------------------- (Principal Executive Officer) August 5, 2003
Lawrence M. Gordon
/s/ Stanley G. Schutzbank President August 5, 2003
- -------------------------
_________________________ Director August 5, 2003
Sheldon L. Glashow
/s/ Donald W. Anderson Controller (Principal August 5, 2003
- ------------------------- Accounting and Financial
Donald W. Anderson Officer)
The foregoing constitutes a majority of the members of the Board of
Directors.
CERTIFICATIONS
I, Lawrence M. Gordon, certify that:
1. I have reviewed this annual report on Form 10-K of Interferon Sciences, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this annual report is
being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date of
this annual report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and
b) any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal controls; and
6. The registrant's other certifying officer and I have indicated in this annual
report whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.
Date: August 5, 2003
/s/ Lawrence M. Gordon
- ------------------------
Lawrence M. Gordon
Chief Executive Officer
CERTIFICATIONS
I, Donald W. Anderson, certify that:
1. I have reviewed this annual report on Form 10-K of Interferon Sciences, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this annual report is
being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date of
this annual report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and
b) any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's
internal controls; and
6. The registrant's other certifying officer and I have indicated in this annual
report whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.
Date: August 5, 2003
/s/ Donald W. Anderson
- ------------------------
Donald W. Anderson
Controller (Principal
Accounting and Financial Officer)
INTERFERON SCIENCES, INC. AND SUBSIDIARY
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Additions
Balance at Charged to Balance at
Beginning Costs, Provisions End of
Description Of Period and Expenses Deductions(a) Period
Year ended December 31, 2002
Valuation and qualifying
accounts deducted from assets
to which they apply:
Reserve for excess inventory $5,538,413 $ $ 859,754 $4,678,659
Year ended December 31, 2001
Valuation and qualifying
accounts deducted from assets
to which they apply:
Reserve for excess inventory $6,123,311 $ $ 584,898 $5,538,413
Year ended December 31, 2000
Valuation and qualifying
accounts deducted from assets
to which they apply:
Reserve for excess inventory $6,991,185 $ $ 867,874 $6,123,311
Notes:
(a) Deductions are for the usage of a portion of the reserve for excess inventory.
INDEX TO EXHIBITS
Exhibit Number
3.1 - Restated Certificate of Incorporation of the Registrant. Incorporated
herein by reference to Exhibit 3B of the Registrant's Annual Report on Form
10-K for the year ended December 31, 1988.
3.2 - Certificate of Amendment of Restated Certificate of Incorporation of the
Registrant. Incorporated herein by reference to Exhibit 3.4 of Registration
Statement No. 33-40902.
3.3 - Certificate of Amendment of Restated Certificate of Incorporation of the
Registrant. Incorporated herein by reference to Exhibit 3.2 of Registration
Statement No. 33-40902.
3.4 - Certificate of Amendment to the Restated Certificate of Incorporation of
the Registrant. Incorporated herein by reference to Exhibit 3.4 of
Registration Statement No. 33-00845.
3.5 - Certificate of Amendment to the Restated Certificate of Incorporation of
the Registrant. Incorporated by reference to Exhibit 3.5 of the
Registrant's Annual Report on Form 10-K for the year ended December 31,
1996.
3.6 - By-Laws of the Registrant, as amended. Incorporated herein by reference
to Exhibit 3.2 of Registration Statement No. 2-7117.
10.1 - Transfer and License Agreement among National Patent, Hydron
Laboratories, Inc. and the Registrant dated as of January 1, 1981.
Incorporated herein by reference to Exhibit 10.8 of the Registrant's
Registration Statement No. 2-71117.
10.2 - Registrant's 1981 Stock Option Plan, as amended. Incorporated herein by
reference to Exhibit 10.3 to Registration Statement No. 33-59479.
10.3 - Agreement, dated as of April 1, 1997, between the Registrant and the
American National Red Cross. Incorporated by reference to Exhibit 10.54 of
the Registrant's Quarterly Report on Form 10-Q for the quarter ended June
30, 1997.
10.4 - Agreement dated May 27, 1997, between the Registrant and Alternate Site
Distributors, Inc. Incorporated by reference to Exhibit 10.55 of the
Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30,
1997.
10.5 - Employment Agreement, dated as of October 1, 1997, between the Registrant
and Lawrence M. Gordon. Incorporated by reference to Exhibit 10.59 of the
Registrant's Annual Report on Form 10-K for the year ended December 31,
1997.
21.0 - Subsidiaries of the Registrant. *
23.1 - Consent of Eisner LLP.*
- -----------------
*Filed herewith
Exhibit 21
Subsidiaries of the Registrant
Name Jurisdiction
Interferon Sciences Development Corporation Delaware
Exhibit 23.1
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in the Registration Statement of
Interferon Sciences, Inc. (the "Company") on Form S-8 (No. 333-49386) of our
report dated June 10, 2003 on our audit of the consolidated financial statements
of the Company as of December 31, 2002 and 2001 and for each of the years in the
three-year period ended December 31, 2002, and the related financial statement
schedule, which report is included in this Annual Report on Form 10-K.
Our report contains an explanatory paragraph that states the Company has
suffered recurring losses from operations, has an accumulated deficit, a working
capital deficiency, and has limited liquid resources. These factors raise
substantial doubt about the Company's ability to continue as a going concern.
The consolidated financial statements do not include any adjustments that might
result from the outcome of that uncertainty.
Eisner LLP
New York, New York
August 4, 2003